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Epstein-Barr virus (EBV) is a human-specific B lymphotrophic 
gammaherpesvirus which causes life-long latent infection.  Although latent 
infection is mainly asymptomatic and thus inconsequential in the majority of 
cases, EBV latency is also consistently associated with many aggressive 
hematological and solid tissue malignancies of diverse tissue origins in 
different populations throughout the world.  The ubiquitous presence of the 
virus in more than 90% of the adult human population and the benign nature 
of latent infection make the pathogenic role of EBV questionable and thus 
many critics claim that the virus is simply an innocent bystander in most of the 
associated malignancies and does not play a direct causal role in 
tumorigenesis.  Clinical evidences from post-transplant lymphoproliferative 
diseases have implied a direct causative role of EBV in pathogenesis.  
However, requirement for additional factors including signaling components 
and cytokine support from T lymphocytes were also identified as essential in 
the rapidly fatal spectrum of lymphoproliferative disease.  In this study, we 
describe a humanized mouse model that incorporates the clinical, virological 
and immunological features of latent EBV infection.  We employ a secondary 
adoptive transfer lymphoproliferative disease model to prove the tumorigenic 
potential of EBV-infected B lymphocytes in severely immunocompromised 
mice.  These data strongly suggest that B lymphocytes in infected hosts are 
both necessary and sufficient for the development of fatal systemic 





with the B lymphocyte depleting antibody Rituximab further highlighted the 
pivotal role of B lymphocytes in the pathogenesis of the disease.  Taken 
together, these data provide the first unequivocal evidence for a causal link 
between Epstein-Barr virus infection of human B cells with 
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CHAPTER 1 :  INTRODUCTION 
1.1 EPSTEIN-BARR VIRUS LIFE CYCLE 
Epstein-Barr Virus (EBV) is a ubiquitous human-specific virus found in over 
90% of the adult population worldwide according to seroepidemiology 1.  It is 
a large double-stranded DNA virus (172 kbp) 2 and belongs to the gamma-
herpesvirus subfamily of the human herpesvirus super family, which is 
characterized by life-long latent infection and periodic reactivation.  The virus 
primarily infects B cells but viral genomes have also been found in T cells and 
natural killer (NK) cells in chronic active EBV infection.  The virus is also 
postulated to infect oropharyngeal epithelial cells.   
Primary childhood infection is usually asymptomatic but the primary 
infection in adolescents is manifested by non-life-threatening self-limiting 
infectious mononucleosis (IM) or glandular fever accompanied by flu-like 
syndrome and systemic lymphadenopathy 3.  The mode of transmission is by 
inoculation of infected saliva.  EBV infects B lymphocytes by engaging its 
envelope protein gp350/220 with CD21 (complement receptor 2) 4.  The 
invasion of the virus into non-B cells, oropharyngeal epithelial cells and 
tissues like smooth muscle, gastric epithelium and other cell types that do not 
express CD21 suggests the involvement of additional as yet undefined host 
receptors for this virus.  According to current model of EBV life cycle, the 
virus invades the oropharyngeal epithelium and infects naïve B cells in the 
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subepithelial lymphoid tissues.  EBV drives massive proliferation of infected 
B cells and expresses lytic as well as some latent proteins that elicit a strong 
cytotoxic T lymphocyte (CTL) response, which destroys the infected B cells.  
During acute infection and reactivation, EBV undergoes a lytic replicative 
cycle in which overwhelming production of virus progeny results in host cell 
rupture and cytopathology.  The virus, after some time, adopts the latent life 
cycle, associated with a limited transcriptional activity, evading immune 
recognition by the host CTLs, and enabling life-long persistence in the 
memory B cell compartment with periodic reactivation5.  A comprehensive 












Figure 1. Epstein-Barr virus (EBV) life cycle.  Epstein-Barr virus 
(EBV) is transmitted by contact with the infected saliva.  The current concept 
holds that EBV invades the nasopharyngeal mucosa and infects circulating B 
lymphocytes in the subepithelial lymphoid tissues.  Infection of 
nasopharyngeal epithelium is controversial.  EBV causes massive proliferation 
of infected B lymphocytes which prime cytotoxic T lymphocytes (CTLs) 
important for the immune clearance of EBV-transformed B cells.  EBV drives 
maturation of the infected B cells into memory B cells which move into the 
peripheral circulation.  Differentiation of memory B cells into plasma cells on 
antigen exposure triggers the lytic EBV life cycle, resulting in the release of 
virus particles which infect B lymphocytes in the vicinity and shed in the 
saliva to infect new susceptible hosts.  Physiological homeostasis of the 
memory B cell compartment maintains the life-long persistence of the virus. 
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1.2 EBV AND THE IMMUNE SYSTEM 
Cytotoxic T cell immunity is the mainstay of the human immune defense 
against EBV infection and virus-induced B cell proliferation.  In 
immunocompromised patients, such as those on post-transplant 
immunosuppressive drug regimes, those receiving cancer chemotherapy, or 
patients with AIDS, suppression of T cell function results in an outgrowth of 
EBV-transformed B lymphocytes, which give rise to lymphoproliferative 
disorders that have high mortality rates 6,7.  This problem is particularly 
marked in transplant patients receiving immunosuppressive drug regimes.  In 
many cases, the lymphoproliferative disorder is controlled by reducing 
immunosuppression which results in an increased risk of graft rejection.  This 
reflects the important role of CTLs in controlling EBV-induced 
lymphoproliferation.   
 
 1.2.1 CD8+ cytotoxic T cell (CTL) responses 
CD8+ T cells are massively expanded in acute symptomatic EBV infection 
(infectious mononucleosis) and the expanded cells exert functional, EBV-
specific, oligoclonal CD8 responses which strongly skew towards immediate 
early and certain early lytic proteins 8.  Up to 40% of the total CD8+ T cell 
population is EBV-specific.  CTL responses against latent proteins are 
relatively smaller and tend to focus strongly on epitopes derived from the 
EBNA3A, B, C family of proteins and the frequency of specific cells comprise 
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up to 5% of total CD8+ T cells 9.  In the late stages of infection and in healthy 
carriers, the frequency of CD8+ T cells specific to latent epitopes selectively 
increases, implying that CTLs are the most important cells responsible for the 
long term control of the virus 10.  There is an age-related expansion of EBV-
specific CTLs which comprise up to 14% of total CD8+ T cell population in 
healthy carriers over 60 years of age 11. 
 
1.2.2 CD4+ helper T cell responses 
The CD4 response in acute infection, is more widely spread across immediate 
early, early and late antigens and the frequencies are much lower compared to 
the CD8 response 12.  The CD4 memory response against lytic antigens has 
been documented but not comprehensively characterized.  Latent antigen-
specific CD4+ T cell response is relatively spread across EBNAs - more 
towards EBNA1 and EBNA2 in contrast to EBNA3-skewed CD8 response 
13,14.  LMP1 is a subdominant CD4 epitope but this latent protein and derived 
peptides stimulate IL10 production in vitro 15, suggesting that LMP1 may 
induce Treg-like cells 16.  The frequency of EBV-specific CD4+ T cells is 
much lower than that of CD8.   
A diagrammatic representation of the immunodominance pattern of 
CD8 and CD4 epitopes in healthy virus carriers is given below in Figure 2 





Figure 2. Immunodominance pattern of selected lytic and latent EBV antigens in healthy virus carriers.  Blue boxes 
represent lytic (IE – immediate early; E – early; L – late; n.t. – not tested) and latent EBV proteins, epitopes derived from which 
are recognized by CD4+ or CD8+ T cells.  Solid arrows denote relative immunodominance of defined epitopes and the height of 
the arrows reflects relative abundance of the response against respective epitopes.  Dotted arrows show documented epitopes 
whose relative immunodominance is not yet determined.  During the lytic replicative cycle of EBV, the majority of the CD8+ 
CTL responses target immediate early lytic and some early lytic proteins.  CD4+ T cell responses, although poorly studied, appear 
to be more widespread across lytic antigens.  In latent EBV infection, the EBNA3 group of nuclear antigens are the most 
immunodominant in terms of CD8+ CTL response, followed by LMP2 and EBNAs.  The CD4+ T cell response is more widely 
distributed across latent antigens and is skewed towards EBNA1, EBNA2 and EBNA3C with some contribution from EBN3A, 
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1.2.3 EBV and NK cells 
Expansion of activated NK cells in the blood of acute infectious 
mononucleosis patients was reported and the cell number was inversely 
correlated with virus load 18.  In vitro experiments also showed that NK cells 
from human tonsil can be primed by co-resident dendritic cells to produce 
IFN-γ which delays the outgrowth of EBV-transformed B cells 19.  However, 
clinical evidence in T cell depleted stem cell transplant patients did not 
support a major role for NK cells in the control of EBV-transformed B cell 
outgrowth in vivo - lymphoproliferative disease is most common in the first 
three to six months post-transplant, by which time NK cell numbers have 
usually recovered 20.  Several EBV gene products have inhibitory effects on 
MHC class I expression on the infected cell’s surface and this may render 
infected cells susceptible to NK-mediated recognition and lysis.  However, 
EBV microRNA (miR-BART2) has recently been shown to reduce expression 
of the NK activating ligand MIC-B, thereby nullifying the susceptibility of the 
infected cells to NK-mediated lysis 21.  
    
1.2.4 EBV and the human cytokine system 
Both acute lytic EBV infection and latent persistence are closely linked with 
cytokines and chemokines which shape the immune response in the 
microenvironment of the infected cells.  Furthermore, EBV genome encodes 
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an IL10 homolog and several proteins which regulate the expression and 
biological functions of cytokines 22.  
Cytokines play a major role in the pathogenesis of acute infectious 
mononucleosis in which patient sera were shown to be rich in IL1α, IL2, IL6, 
and IFN-γ 23.  Release of cytokines and chemokines results from massive 
expansion of activated CTL clones which is a characteristic pathological 
feature of acute IM.  EBV-infected cells in the tonsil of acute IM patients 
express lymphotoxin, TNF-α, IL6, IFN-γ 24, IL18, monokine induced by IFN-γ 
and IFN-γ inducible protein 10 (IP10) 25  while EBV-negative interfollicular 
cells expressed IL1α, IL1β and IL8.   
Among other cytokines and chemokines, IL6 is closely linked in EBV 
infection and immunodeficiency-associated lymphoproliferative disease.  
Cross-linking of CD21 by viral envelope glycoprotein gp.350/220 induces 
expression of IL6 26, which activates NF-κB in lymphocytes 27 and regulates B 
cell growth and differentiation during primary EBV infection.  IL6 also acts as 
an autocrine growth factor for EBV-immortalized B cells 28.  IL6 promotes the 
growth of B cells in lymphoproliferative disease and anti-IL6 antibodies 
decrease the incidence of the tumor 29, highlighting the role of IL6 in disease 
progression.   
EBNA1-specific helper T cells were shown to preferentially secrete a 
Th2-type cytokine IL5 in response to antigenic stimuli 30.  However, another 
group reported that the cytokine secretion of EBNA1-specific helper T cells 
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was polarized towards a Th1 pattern IFN-γ secretion 31.  Secretion of IL8 and 
macrophage inhibitory protein 1α (MIP-1α) was triggered by EBV binding of 
monocytes and the secretory response was enhanced by GM-CSF 32.  GM-CSF 
was also known to facilitate the spontaneous outgrowth of EBV-infected B 
cells 33.  GM-CSF orchestrates the host immune response towards virus 
eradication but at the same time, facilitates more infection events as the 
immune cells are recruited to the site of infection. 
Th1 cytokines IFN-γ and TNF-α were reported to be expressed in the 
lymph nodes of infectious mononucleosis patients but not in those of 
lymphoproliferative disease 25.  IL18, which induces IFN-γ expression, acts 
together with IL12 and IP10 caused the regression of EBV-positive Burkitt’s 
lymphoma 34. 
The cytokine profile in post-transplant lymphoproliferative disease was 
reported to be skewed towards a Th2 pattern with IL2- IFN-γ- IL4+ IL10+ 
profile by using semi-quantitative RT-PCR, suggesting that PTLD was 
developed in a Th2 cytokine milieu 35.  Th2 polarization in PTLD may reduce 
the host CTL response which requires Th1 cytokines, and favor the growth of 
tumor cells in autocrine fashion.  Furthermore, Paul, et al. 36 showed EBV-
transformed B lymphoblasts secrete Th2 cytokine IL5.  The same group also 
reported that GM-CSF modulated the spontaneous outgrowth of B 
lymphoblastoid cell clones after in vitro infection 33. 
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EBV encodes several cytokine homologs and regulatory factors to 
manipulate the host cytokine response to abrogate the anti-viral immune 
response.  EBV-encoded viral analog of IL10, EBV-induced gene 3 (EBI3) 
and BARF1 proteins regulate the secretion and biological actions of several 
human cytokines and thus important for evasion of immune response 
(elaborated in Section 1.2.6 – Immune evasion mechanisms).  EBNA2, which 
is a transcriptional transactivator, regulates the expression of lymphotoxin, 
TNF-α and G-CSF in EBV-infected B cells 37.  LMP1 can induce the secretion 
of IL6, IL8, IL10 and IFN regulatory factor-7 (IRF7) to favor the survival of 
host cells 38-40.  
 
1.2.5 Anti-EBV antibody responses 
The function of the anti-EBV humoral immune response is to limit the 
infectious virus particles and therefore, to control the spread of the virus in the 
late stages of infection 41.  Important antibody targets include the early antigen 
complex, which comprises several immediate early and early EBV proteins 
including the lytic cycle transactivator BZLF1, and the late structural viral 
capsid antigen complex early in infectious mononucleosis.  In addition, the 
membrane antigen complex, including gp350, induces neutralizing antibodies 
in acute IM 42.  Thus by the onset of clinical symptoms, high titers of anti-viral 
capsid antigen IgM and IgG as well as IgG against early antigen and 
membrane antigen complexes can be detected.  IgA against viral capsid 
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antigen and early antigen complexes may also be transiently expressed.  IgG 
to EBNA1 and less consistently to EBNA2, 3A, 3B, 3C, and LP develop late 
during IM and are often still rising after the infected host has made a full 
recovery.  IgG against viral capsid antigen, membrane antigen complex gp350, 
and EBNA1 are consistently detected in healthy carriers after recovery from 
primary infection.  Titers vary between individuals but tend to remain stable 
throughout life 1. 
 
1.2.6 Immune evasion mechanisms of EBV 
EBV adopts various immune evasion mechanisms to enable its long-term 
persistence in the host.  The EBV life cycle is closely related to normal B cell 
differentiation and maturation pathways and the population of virus reservoir 
memory B cells is subject to control by normal homeostatic mechanisms 43.  
During the latent stages of infection, the transcriptional machinery of EBV is 
altered to express a restricted set of genes representing different latency 
programs in B cell subsets.  EBV antigen expression ultimately shuts down in 
memory B cells which serve as the virus reservoir, effectively avoiding 
recognition by CTLs. 
 In addition, several EBV gene products have been reported to perturb 
both MHC class I and class II antigen processing and presentation pathways22.  
The glycine-alanine repeats within the EBNA1 protein are proposed to inhibit 
degradation by the ubiquitin-proteasome system and subsequent antigen 
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processing pathway, thereby preventing presentation of EBNA1 epitopes in 
the context of MHC class I molecules on the cell surface 44.  A lytic cycle 
protein BNLF2 prevents peptide loading to MHC class I through inhibition of 
the Transporter associated with Antigen Processing-1 (TAP1) 45.  Synthesis of 
new MHC class I molecules is blocked by the viral DNAse, BGLF5 46 and 
those present at the cell surface are downregulated by another lytic protein 
BILF1 47.  During lytic cycle, Zta protein (BZLF1) downregulates expression 
of the class II transactivator CIITA protein, resulting in reduced expression of 
MHC class II molecules for antigen presentation on the cell surface 48.  
Furthermore, the BZLF2 protein binds to the β-chain of MHC class II 
molecules and blocks the presentation of class II-restricted CD4+ T cell 
epitope 49. 
 Apart from the perturbation of antigen presentation, several EBV 
proteins disturb the cytokine balance of the disease microenvironment to favor 
the survival of infected host cells.  EBV encodes cytokine homologs and 
regulatory factors to manipulate the host cytokine response to abrogate the 
anti-viral immune response.  The BCRF1 protein of EBV, also known as viral 
IL10 (vIL10), exhibits 78% identity in amino acid sequence with human IL10.  
vIL10 has profound effects on both MHC class I and class II presentation 
pathways and mimics a subset of immunoinhibitory effects of human IL10 50-
52.  For example, viral IL10 (vIL10) inhibits IFN-γ secretion through negative 
regulation of IL12 to suppress IFN-γ-mediated T cell activation 53.  EBV-
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encoded gene 3 (EBI3) binds to the p35 subunit of IL12 and the heterodimer 
modulates IL12-dependent cell-mediated immunity 54.  BARF1 protein 
functions as a decoy receptor for colony-stimulating factor 1 (CSF1) 55 which 
enhances the expression of IFN-α in monocytes, thus disturbing the innate arm 
of EBV immunity, thereby evading the host immune response during 
infectious mononucleosis and reactivation of the virus in latently infected cells 
56.   
In summary, EBV has a complex interaction with the human immune 
system and the virus has evolved a myriad of evasion mechanisms through 
controlled expression of lytic and latent proteins and secretion of soluble 
factors that influence the disease microenvironment and host immunity.          
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1.3 LATENT EBV INFECTION 
Latent EBV infection is characterized by the expression of a restricted set of 
viral genes.  Latency programs are associated with different stages of the 
physiological B cell differentiation and maturation pathway in healthy hosts 43 
and their disease counterparts in EBV-associated disease conditions 57.  The 
EBV genome exists as an extrachromosomal circularized episome in latently 
infected cells and expresses up to six nuclear antigens (EBNA1, 2, 3A, 3B, 
3C, LP), two latent membrane proteins (LMP1, LMP2), and non-coding RNAs 
(EBERs).  (See Figure 3, Table 1 and Table 2)  Latent EBV gene products are 
proposed to be responsible for most of the EBV-induced transformation events 
and so play critical roles in the pathogenesis of EBV-associated 
malignancies58.  Moreover, latent EBV proteins form a tightly controlled 
interactive network that includes host cell growth, differentiation and 
apoptotic pathway components.  This ensures the persistence of the virus for 
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Figure 3. The structure of the circular plasmid-like genome of the 
prototypic B95-8 strain of EBV in latently infected cells.  Segments of the 
genome labeled with single alphabet characters indicate BamHI restriction 
fragments.  Blue boxes represent cis-active elements of EBV:  OriP and oriLyt 
are origin of replication in plasmid DNA and lytic cycle respectively and TR 
represents the packaging signal of viral DNA.  Turquoise boxes indicate 
EBNAs – EBV nuclear antigens and respective promoters – Qp, Cp and Wp.  
Magenta boxes show latent membrane proteins – LMP1 and LMP2.  Red 
arrows indicate non-coding RNAs, namely EBERs, EBV mi-RNA rich 
clusters BHRF1 and BART.  Yellow boxes represent lytic genes BZLF1, 
BHRF1, BALF1 and BCRF1 (viral analog of IL10) which are expressed 
during early stages of the infection.  
(This figure is adapted from Kalla and Hammerschmidt 59) 
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Table 1. Latent EBV gene expression programs.  EBERs are 
expressed in all latency programs.  In addition, LMP2A is expressed in 
resting memory B cells and is termed latency 0 or latency program.  EBNA1 is 
transcribed from the Qp promoter in latency I and II programs and Cp/Wp 
promoter in the latency III program.  Latent membrane proteins, LMP1 and 
LMP2, are expressed in latency II and III programs.  A complete set of latent 
EBV genes is expressed in latency III program.    
 
 
Table 2. EBV latency gene expression programs in physiological B 
cell maturation stages and disease associations.  A true latency program is 
expressed in resting memory B cells and does not have any reported disease 
associations.  Latency I genes are expressed in dividing memory B cells and 
Burkitt’s lymphoma cells.  Latency II program is found in germinal center B 
cells and is associated with Hodgkin’s lymphoma, and non-B cell 
malignancies such as NK/T cell lymphoma and nasopharyngeal carcinoma.  
Latency III program is expressed in newly transformed B cells and 
immunodeficiency-related lymphoproliferative diseases.  A lytic program is 
expressed in plasma cells, B cells in acute infectious mononucleosis and post-
transplant lymphoproliferative diseases. 
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1.3.1 EBV-encoded RNAs (EBERs) 
EBERs are expressed abundantly (~106 copies per cell) in EBV-positive cells 
and EBER in situ hybridization 60 is a gold standard employed to detect EBV 
in tissues.  The functional role of EBERs in virus biology and EBV-related 
malignancies has not been well-defined.  EBERs were reported to mediate 
prevention of apoptosis 61, suppress anti-viral effects of IFN-α and IFN-γ 62 
and induce the secretion of an autocrine growth factor IL10 in Burkitt’s 
lymphoma cell lines 63.  EBERs also play a critical role in efficient in vitro B 
cell transformation induced by EBV 64.   
 
1.3.2 Latency I or ‘EBNA1 only’ program 
In latency I (EBNA1 only) program, EBV nuclear antigen-1 (EBNA1) is the 
only viral protein expressed in the host cells in addition to EBERs.  The 
expression of EBNA1 is driven by different promoters in latent EBV infection 
– Q promoter in latency I and II programs and C or W promoter in latency III 
program.  In latency I program, EBNA1 mRNA is transcribed from the Q 
promoter.  EBNA1 is responsible for maintenance of the viral genome in the 
episomal form by interaction with the origin of replication (OriP), hence the 
name genome-tethering protein 65,66.  A long glycine-alanine repeat region in 
EBNA1 was reported to inhibit the ubiquitin-proteasome system which is 
required to generate antigenic peptides to be presented with MHC class I 
molecules for immune recognition 44.  Therefore, by maintaining the latent 
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form of the viral genome and avoiding immune recognition, the latency I 
program of gene expression ensures the persistence of the virus inside host 
cells that under normal circumstances do not proliferate but stay dormant in 
the circulation as the virus reservoir.  The latency I program is found in 
peripheral memory B cells in healthy persons.  EBV-positive Burkitt’s 
lymphoma cells were also shown to express the latency I pattern 67.    
 
1.3.3 Latency II or the ‘Default’ program 
Latency II, also known as the default program is characterized by expression 
of EBERs, EBNA1 and the latent membrane proteins, LMP1 and LMP2A.  In 
healthy persons, latency II is found in B cells undergoing germinal center 
maturation.  A disease association with the latency II gene expression program 
was first described in nasopharyngeal carcinoma 68, a lymphoepithelial tumor 
with a very strong association with EBV.  Hodgkin’s lymphoma and NK/T 
cell lymphoma were also found to be associated with this type of latency 69,70.  
Latency II cells express latent membrane proteins which are important for 
EBV-induced B cell transformation.  LMPs have signaling functions that can 
mimic the signals required for normal physiological B cell maturation.   
LMP1 is a putative oncoprotein that has a remarkable transforming 
ability in rodent fibroblasts 71 and promotes tumor formation in 
immunodeficient mice.  The signaling function of LMP1 is analogous to CD40 
activation in B cells and therefore, acts as a constitutively active TNF 
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receptor72.  LMP1 recruits TNF receptor associated factors (TRAFs) and TNF 
receptor-associated death domain proteins (TRADD), resulting in the 
activation of the NF-κB pathway 73-75 and induces the upregulation of anti-
apoptotic proteins Bcl-2 76,77 and A20 78.  Activation of cellular signaling 
pathways is responsible for the dramatic morphological changes observed 
during EBV- transformation of B cells such as cell clumping, appearance of 
villipodia and upregulation of cell activation markers such as MHC class I, 
CD21, CD23, CD44, CD95, etc.   
LMP2 is another latent EBV protein which has signaling functions and 
it acts as a constitutive dominant negative modulator of the B cell receptor and 
delays or interferes with the onset of lytic replication inadvertently triggered 
by other B cell stimulatory factors 79.  Although LMP2 is not required for B 
cell immortalization 80, it maintains the infected B cells in a latent state and 
prevents reactivation with associated lytic replication of EBV 81.  However 
latency II cells lack EBNA2 required for induction of cell proliferation so 
latency II cells are not induced to proliferate unless there are additional 
cellular changes and growth promoting signals in the microenvironment. 
 
1.3.4 Latency III or the ‘Growth’ program 
The full set of EBNAs (EBNA1, 2, 3A, B, C and EBNA-LP) is expressed 
together with EBERs and LMPs in the latency III gene expression program 
(also termed the growth program) 82.  Expression of six nuclear antigens are 
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regulated by C and W promoters and translated from spliced products of a 
giant messenger RNA.  EBNA2 is another transforming protein and acts as a 
viral transcriptional transactivator responsible for induction of proliferation of 
EBV-infected cells 83.  It also upregulates the expression of LMP1 and 
LMP284, as well as cellular proteins which enhance growth and transformation 
of B cells.  EBNA3 family members 3A and 3C are reported to be essential for 
B cell immortalization 85.  EBNA-LP was also shown to greatly enhance the 
immortalization process 86,87 and enhance EBNA2-mediated transcriptional 
activation 88.  Therefore, EBNA2, 3A, 3C, EBNA-LP and LMP1 are essential 
for B cell immortalization while EBNA1 and LMP2 are critical for 
maintenance of the EBV episome and the latent state respectively.  The 
latency III gene expression program is uniquely found in B lymphocytes - in 
vitro transformed B cells and immortalized B lymphocytes during early stages 
of the viral life cycle before the host CTL response is initiated.  B cells in 
immunodeficiency-related lymphoproliferative diseases like post-transplant 
lymphoproliferative disease, immunoblastic lymphoma and AIDS-related 
lymphomas also express the latency III pattern of EBV genes. 
 
1.3.5 Other latency programs 
In additional to these three main latency programs, EBV expresses only 
EBERs and LMP2A (latency 0 or the true latency program) in resting memory 
B cells circulating in the peripheral blood.  On the other hand, the expression 
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of EBNA2, but not LMP1 during the lytic phase of the infection is called 
latency IV or lytic program 58.   
 
1.3.6 Regulation of EBV latency 
The earliest events in the establishment of latent EBV infection are initiated 
immediately post-infection when EBV gene transcription is initiated by the W 
promoter resulting in the expression of EBNA-LP and EBNA2.  These two 
nuclear proteins activate and drive another promoter, Cp, which transcribes all 
the nuclear antigens, the most important of which in this context is EBNA1.  
EBNA1 binds to oriP (origin of plasmid replication) and initiates replication 
of viral DNA and expression of all EBNAs and LMP1 in concert with host 
DNA replication 66,89.  Binding of EBNA1 to oriP upregulates transcription 
from the C promoter.  EBNA1 tethers the circular episome to genomic DNA 
and ensures replication and equal division of EBV genome into daughter cells 
after each cell division 90.  The W promoter uses host cell transcription factors 
while the C promoter is tightly controlled by EBNA1 and other viral factors.  
The switch from the W to the C promoter is an important event to gain 
autonomy in viral replication and transcription.  However, EBV-associated 
tumors in immunocompetent hosts express either latency I (e.g., Burkitt’s 
lymphoma) or latency II (e.g., Hodgkin’s lymphoma) programs which do not 
include the full range of latent EBV proteins.  In those tumors, EBNA1 is 
expressed from another more restricted Q promoter 91, which lacks a TATA 
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element and functions similar to promoters for housekeeping cellular genes 
thus ensuring ongoing expression of EBNA1 in the absence of transcriptional 
initiation from the C and/or W promoters.  The Q promoter exclusively 
expresses EBNA1 without other nuclear antigens and EBNA1 exerts a 
negative feedback effect on the Q promoter 92.  The preferential usage of the Q 
promoter is due to lack of methylation on this promoter while C and W 
promoters are heavily methylated in EBV-associated tumors in 
immunocompetent hosts 93.  Latency is maintained by the constitutively active 
B cell receptor-like action of LMP2 which effectively blocks other BCR-
activating signals as discussed in Section 1.3.3 ‘Latency II or the ‘Default’ 
program’.   
 
1.3.7 The persistence of EBV 
Dissection of healthy tonsil tissues from EBV-infected individuals to allow an 
analysis of the latency programs revealed the latency III program in naïve B 
cells, latency II program in germinal center B cells, latency I program in 
resting memory B cells and the lytic program when B cells terminally 
differentiate into plasma cells 43.  These findings indicate that EBV latency 
programs are closely aligned with the normal B cell differentiation and 
maturation pathways.  Proliferating activated lymphoblasts have a similar 
phenotype (latency III or growth program) to EBV infected naïve B cells so 
the current model holds that EBV infects naïve B cells and drives the cells 
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through the normal differentiation pathway to become memory B cells where 
the virus persists for long periods without a risk of being detected by the 
immune system.   
The functions of EBV viral proteins expressed during latency support 
the validity of this model.  LMP1 signaling mimics one of the principal signals 
from CD4+ T cell help - constitutive CD40 signaling - and LMP2 provides the 
BCR-like signal which is essential for continued survival of activated 
lymphoblasts and maturation through the germinal center.  The only other 
EBV protein expressed in germinal center B cells is EBNA1 which helps 
maintain the viral episomes throughout the maturation process.  Ultimately, 
the activated B cells mature into memory B cells or plasma cells.  EBV shuts 
down its transcription program in memory cells which exit the cell cycle and 
stay dormant in the circulation of the host.  In the peripheral blood, EBV is 
exclusively found in the memory B cells 5 which serve as the virus reservoir.  
EBV in plasma cells expresses the lytic cycle and exposes more cells for 
infection with the virus to help maintain life-long latent infection within the 
host.  However, the mechanism of latency switch as the infected naïve B cells 
mature and differentiate into memory B cells is still not known and remains 
unexplained by this model.   
An alternative explanation for the persistence of EBV has been 
proposed 94,95.  This postulates that EBV directly infects memory B cells in the 
germinal center and that EBV-infected B cells do not participate in the 
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germinal center reaction.  This hypothesis is based on the evidence that 
EBNA2-expressing EBV-infected cells (latency III or growth program), 
undergoing clonal expansion were found in the germinal centers of the 
patients with infectious mononucleosis.  But the counter-argument is that 
EBV-infected naïve B cells rapidly differentiate into resting memory cells in 
the germinal center as described by the first model and the high level of 
viremia in the germinal centers in infectious mononucleosis causes the 
infection of bystander germinal center cells, pushing them into the latency III 
growth program and these constitute the majority of the cell population 
observed by Kurth, et al.  The observations by Ehlin-Henriksson, et al. 96 
supports part of the counter-argument as they report that all B cell subsets 
(naïve or memory) were equally susceptible to EBV infection in vitro.  
Eventually these bystander infected germinal center cells will be eliminated by 
the host CTL response and only those germinal center cells which express 
latency II or default program will remain and constitute the EBV positive cells 
in the healthy hosts.  These remaining cells will differentiate into memory B 
cells.  
The population of virus reservoir memory B cells is stably maintained 
by the same physiological homeostatic mechanisms 97 as the general mucosa-
associated memory B cell pool.  Therefore, EBV effectively hijacks the 
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Understanding EBV latency and persistence is the key to 
understanding the pathogenic role of this virus in associated lymphoid 
malignancies and some non-lymphoid solid tissue malignancies.  Since EBV 
is almost omnipresent in the normal healthy adult population worldwide and 
latent EBV infection is almost always asymptomatic and inconsequential, the 
role of EBV in associated malignancies is often questioned by critics.  Whilst 
evidences are accumulating that suggest that EBV is more than a bystander in 
malignant transformation, there is no strong evidence that supports the idea 
that EBV actually causes those malignancies though it has been noted that 
EBV-associated tumors usually harbor a monoclonal viral genome suggesting 
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1.4 EBV-ASSOCIATED MALIGNANCIES AND THE ROLE OF 
EBV IN TUMORIGENESIS 
Epstein-Barr virus (EBV) is the first human DNA tumor virus discovered in 
1964 by electronmicroscopy of cells cultured from Burkitt’s lymphoma - an 
endemic childhood extranodal lymphoma in sub-Saharan Africa 99.  In the last 
fifty years, EBV has been linked to a large number of malignant tumors 
derived from diverse human tissues.  EBV is found in association with almost 
all cases of endemic Burkitt’s lymphoma in Africa; almost all cases of the 
anaplastic variant of nasopharyngeal carcinoma endemic in southern China 100; 
and 20-40% of Hodgkin lymphoma in the Western world 101,102.  In addition, 
evidence of EBV infection (the virus genome, latent proteins, antibody 
response, etc) in gastric cancer 103,104, and immunodeficiency-associated 
smooth muscle tumors has also been reported 105,106. 
 Disease association is determined by seroepidemiology in some of the 
cases and by demonstration of EBV genome or proteins in tissue lesions and 
hence, such methods do not reflect any causal relationship because of the very 
high prevalence of EBV infection.  We will discuss the role of EBV with the 
emphasis in associated lymphoid malignancies.   
 
1.4.1 EBV and Burkitt’s lymphoma 
Monoclonal viral genomes were detected in Burkitt’s lymphoma 107, implying 
that the virus was present before the malignant transformation.  But the 
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finding was complicated by the discovery of a chromosomal translocation 
involving c-myc on the long arm of chromosome 8 and immunoglobulin 
heavy chain gene on chromosome 14, or less frequently, immunoglobulin light 
chain gene on chromosome 2 or 22, resulting in dysregulation of c-myc 
expression, which has become the defining feature of Burkitt’s lymphoma as 
c-myc translocation is a universal signature of EBV-positive and –negative 
Burkitt’s lymphoma cases 108.  The phenotype of Burkitt’s lymphoma 
(CD10+CD77+BCL6+) is remarkably similar to that of germinal center 
centroblasts and the detection of ongoing immunoglobulin gene mutation109,110 
in the tumor cells implies that the lymphoma originates from those B cells 
which are in the early stages of germinal center maturation.  EBV-transformed 
B cells may provide a pool of target cells at increased risk of c-myc mutation 
during somatic hypermutation in the germinal center.  In vitro model systems 
showed that EBV latency I program was not compatible with molecular events 
engendered by c-myc 111 and that c-myc expression in lymphoblastoid cells 
prevented the switch from latency III to I 112.  The strength of the selection 
against full expression of latent EBV genes is supported by a subset of 
Burkitt’s lymphoma cells which retain the transcriptional features of latency 
III but the viral genomes are devoid of EBNA2 and thus are missing the usual 
transformation function of EBV 113.  Furthermore, the only EBV protein 
expressed in latency I programmed-Burkitt’s lymphoma cells is EBNA1 
which does not have a strong growth promoting action.  Therefore, the 
functional link of EBV in the pathogenesis of Burkitt’s lymphoma is vague 
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and restricted to initiation of cell proliferation during the early stages of the 
infection before c-myc translocation triggers the formation of a full-blown 
lymphoma.   
 
1.4.2 EBV and Hodgkin’s lymphoma 
In parallel with Burkitt’s lymphoma, EBV-associated Hodgkin’s lymphoma 
harbor clonal EBV genomes in all of the malignant Reed-Sternberg cells 101.  
Immunoglobulin gene rearrangement studies on Reed-Sternberg cells revealed 
an accumulation of dysfunctional rearrangement and destructive mutations 114.  
In Hodgkin’s lymphoma cells, EBV expresses a latency II pattern with the 
expression of EBNA1, LMP1 and LMP2.  B cells which accumulate aberrant 
mutations during germinal center reaction are often eliminated by 
programmed cell death.  However, in the case of Hodgkin’s lymphoma, B 
cells harboring destructive mutations may have been rescued by EBV proteins.  
This hypothesis is supported by the signaling function of LMP1 which 
constitutively activates the CD40 pathway, replacing the signal provided by 
cognate T cells during selection of memory B cells and by LMP2 which 
mimics the signal from the B cell receptor after high affinity binding to 
cognate antigens 79.  Another piece of evidence supporting the role for EBV in 
the pathogenesis of Hodgkin’s lymphoma is provided by the strong activation 
of NF-κB activity in the tumor cells - LMP1 is a strong inducer of the NF-κB 
pathway 115.  However, EBV-negative Hodgkin’s lymphomas also show a 
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strong NF- κB activity.  Therefore, it is possible that NF-κB activation is the 
vital step in the malignant transformation process in Hodgkin’s lymphoma and 
the EBV-positive and EBV–negative cases achieve the same goal via different 
routes.   
 
1.4.3 EBV and Immunodeficiency-related lymphoproliferative disease 
When an EBV-seronegative patient receives an organ from a seropositive 
donor, post-transplant lymphoproliferative disease arises from donor B cells as 
there is virtually no host CTL response to control B cell outgrowth – these 
cells typically express latency III pattern of viral genes 116 similar to 
proliferating lymphoblasts in early stages of EBV infection.  These lesions are 
usually polyclonal within the first year after transplantation when T cell 
immunosuppression is most severe.  The proportion of EBV-associated cases 
is much lower beyond the first year of transplantation and the lesions become 
predominantly monoclonal, more lethal, more heterogeneous and more 
resistant to treatment (most do not resolve with reduction of 
immunosuppressive agents and reconstitution of T cell immunity).  The latent 
EBV gene expression pattern is also diverse.  Although most follow classic 
latency III program, several cases with varied gene expression patterns such as 
EBNA2-LMP1- and EBNA2-LMP1+ have been reported 117,118 suggesting that 
additional cellular genetic changes have been acquired which efficiently 
bypass the need for these two oncoproteins in the malignant transformation 
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process, weakening the link between EBV and the disease.  Immunoglobulin 
gene rearrangement studies showed a germinal center or post-germinal center 
pattern of V gene rearrangement and ongoing hypermutation, suggesting 
disruption of germinal center maturation and rescue of such cells by EBV - 
similar to the process proposed for Hodgkin’s lymphoma cells 119.  In 
summary, this diverse group of lymphoproliferative diseases expresses a 
significant degree of overlap in their cellular phenotype and this phenotype is 
also similar to lymphoblasts in the early stages of EBV infection.  However, 
the lack of CTL response is the key to development of full-blown 
lymphoproliferation, rather than the intrinsic tumorigenic properties of B cells 
which form the tumor bulk.   
In conclusion, there is a growing literature suggesting that EBV 
expresses tumorigenic gene products that may have the potential to initiate, 
support and potentiate the malignant transformation process but there remains 
a dearth of direct evidence linking EBV infection to tumorigenesis in vivo.   
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1.5 EBV-ASSOCIATED POST-TRANSPLANT 
LYMPHOPROLIFERATIVE DISEASE (PTLD) 
The first evidence of a link between immunodeficiency and lymphoma was 
based on the epidemiology of cancer in primary T cell immunodeficiency 
syndromes such as Wiskott-Aldrich syndrome, severe combined 
immunodeficiency and ataxia-telangiectasia 120.  The importance of T cell-
mediated immunity is highlighted by this observation and the rising epidemic 
of lymphomas associated with HIV disease and iatrogenic immunosuppression 
with the advent of immunosuppressive medications and transplantation 
technology 121. 
 
1.5.1 Post-transplant lymphoproliferative disease 
Since the first report in 1969, it has become well established that transplant 
recipients (both solid organ and bone marrow) have a high risk of developing 
a lymphoproliferative disorder 122,123.  The risk of developing post-transplant 
lymphoproliferative disorder (PTLD) varies with the type of organ 
transplanted, the age of the patient and the intensity of the immunosuppressive 
regime used.  The highest rate of PTLD is seen in the first year post-
transplant124.  The overall incidence of PTLD is 1 - 2%.  The incidence of the 
disease in renal and liver transplant is 1 – 5%, in heart and heart-lung 
transplant is 5 – 15%, and in intestinal transplant is 10 – 15% 125.  The 
incidence of PTLD in bone marrow transplant is 0.5% in HLA-matched 
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transplants and rises sharply to 15% with T cell depleted highly 
immunosuppressed transplants 126.  Although PTLD is relatively rare, it is the 
most common malignant disease after transplantation.   
The EBV genome has been found in the majority of the PTLD cases 
(>90%).  EBV-induced PTLD manifests as two forms – primary infection and 
reactivation.  EBV seronegative patients (mostly pediatric transplant patients) 
are at higher risk of developing PTLD due to primary EBV infection when the 
donor is EBV-positive.  Most cases of PTLD occurring in previously EBV 
seropositive individuals do not develop for over a year and may present many 
years later post-transplantation 127.  PTLD develops from donor cells in solid 
organ transplant patients and from recipient cells in bone marrow transplant 
patients. 
A hypothetical role of latent EBV proteins in the pathogenesis of 
PTLD has been explained in the previous section covering EBV latency and 
associated malignant diseases.   
 
1.5.2 The role of lytic EBV infection 
The majority of the lymphoid proliferation in PTLD is associated with latent 
EBV infection, 80% of the tumors show EBV lytic cycle reactivation and 30 – 
40% of the tumors contain EBV late antigens or replicative DNA in the linear 
form in addition to the circular episome 128-130.  SCID mice PTLD models 
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using peripheral blood mononuclear cells from seropositive donors showed 
similar findings – two forms of EBV genome in the tumor tissues 131.  
Rochford and Mosier 132 reported that EBV-immortalized B cells in lytic stage 
more readily gave rise to tumors in SCID mice.  These experimental evidences 
suggest that EBV lytic cycle also plays an important role in the development 
of PTLD.   
Evidences from clinical research on PTLD patients support these 
observations and showed the importance of lytic cycle reactivation in disease 
pathogenesis.  Assessment of the EBV viral load in high risk seronegative 
patients is important for the identification and appropriate monitoring of such 
patients 133.  Detection of EBV viremia alone is not always predictive but 
increased viral load combined with a reduction of EBV-specific T cell counts 
allow a more precise prediction of the risk of development of PTLD 134.     
 
1.5.3 The role of cytokines  
EBV-immortalized cells have been shown to express and secrete cytokines 
important for B cell growth and immortalization, chemotaxis, and the 
inhibition of immune recognition and effector functions.  Many of the 
secretory actions identified in these cells are due to potent activation of NF-κB 
and AP-1 pathways by the EBV gene product LMP1.  A cytokine of 
significant importance is IL10.  The EBV BCRF1 gene also expresses a viral 
ortholog of IL10.  This cytokine was found to be raised in the serum of PTLD 
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patients.  IL10 exerts broad inhibitory functions on immune cells in vitro and 
in vivo and it inhibits T cell recognition of EBV-transformed B cells by the 
downregulation of the HLA transport molecule TAP1, resulting in inhibition 
of B cell antigen presentation through the HLA class I pathway 50,51.  IL10 
also prevents the production of IL2, thereby deterring activation of T cells and 
NK cells.  All these actions allow the expansion of early tumorigenic B cell 
clones.  Furthermore, IL6 promotes the growth of B cells in 
lymphoproliferative disease and anti-IL6 antibodies decrease the incidence of 
the tumor 29, highlighting the role of IL6 in disease progression.  Therefore, a 
supportive role of cytokines in the pathogenesis of PTLD is highly likely. 
 
1.5.4 The role of anti-EBV antibodies 
Humoral immune response against EBV provides additional support in 
development of PTLD and is exploited in clinical diagnosis and management 
of the tumor.  Persistence of anti-EA antibodies has been shown to be more 
likely in PTLD patients 135.  In seropositive transplant recipients falling anti-
EBNA1 titer with elevated EBV load may indicate the presence of PTLD 136.  
However humoral immune response of immunosuppressed patients is not 
optimal so serology tests should be interpreted with caution.  The major role of 
EBV serology in the transplant setting is to determine the serological status of 
the donor and recipient to offer informed choice for organ allocation during 
pre-transplant preparatory period. 
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1.5.5 The role of T cell immunity 
Reported analyses of PTLD tissues have revealed an abundance of 
CD4+CD45RO+ helper T cells which expressed low levels of CD28 and 
CD25, reflecting a suggested anergic state of those cells 137.  A SCID mouse 
model of PTLD using sorted peripheral blood mononuclear cells suggested a 
requirement for T cells as tumors only formed when the T cells were injected 
together with EBV-infected B cells which failed to form tumor when injected 
without T cells 138.  CD4+ T cells can provide CD40L signal which in turn 
promotes the expansion of EBV-infected cells by providing the important 
accessory signal required to respond to autocrine factors such as IL6, IL10 or 
TGF-β 139-141.   
The management of PTLD is based on reconstituting T cell immunity 
through a lowering or withdrawal of the patient’s immunosuppressive drug 
regime or by the adoptive transfer of EBV-specific T cells – a form of 
immunotherapy.  This demonstrates the pivotal role of functional T cell 
immunity in suppressing the EBV-induced B cell expansion.  However, this 
approach has only proven effective for treating early polymorphic lesions.  
Monomorphic or late tumors require chemotherapy or B cell depletion therapy 
using Rituximab, suggesting that monoclonal tumors or monomorphic tumors 
resembling a specific type of non-Hodgkin lymphoma (diffuse large B cell 
tumor or plasmacytic lymphoma, etc) that arise from the malignant clone of 
EBV-transformed B cells which acquired additional cellular transformation 
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signals rather than the expansion of EBV-immortalized B cells in the absence 
of suppressive T cell immunity.  In other words, B cells themselves may be 
capable of autonomous proliferation without the requirement of T cell or 
cytokine support – this would represent true malignant transformation.  
However, there is no direct evidence to date to confirm the true malignant 
nature of EBV-infected B cells.     
Summing up the experimental and clinical evidences for the 
pathogenesis of PTLD, the contribution of EBV in the pathogenesis of PTLD 
is not very strong as the virus depends on other factors including immune cells 
and cytokines, etc.  EBV induces tremendous changes in the infected B cell 
phenotype and provides various signals which may be required by B cells to 
expand into a malignant clone but there remains no strong experimental 
evidence to conclusively prove this fact.  Thus, this study was conceived with 
the objective of investigating the nature of EBV-infected B cells and possible 
causal relationship in EBV-linked immunodeficiency-associated 
lymphoproliferative disease.  Since EBV is a human-specific infection, the use 
of a human system is mandatory to study the complex behavior of this virus.  
Thus the humanized mouse technology where the mice harbor a human 
hematoimmune system was reviewed as a platform to study EBV 
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1.6 HUMANIZED MOUSE MODELS OF EPSTEIN-BARR VIRUS 
INFECTION 
Humanized mice were developed from severely immunodeficient mouse 
strains reconstituted with human hematopoietic progenitor cells.  The 
humanized mouse system is an attractive candidate for system level studies of 
various aspects of development of the human hematoimmune system, 
functions of human immune system, human-specific infectious diseases and 
host-pathogen interaction, tumor immunity, etc 142.  Among different 
immunodeficient mouse strains, NOD/SCID/IL2Rγcnull strain (NSG) was 
shown to be the best for reconstitution of the human hematoimmune 
system143,144.  This is because NSG mice carries the true null mutation of the 
interleukin 2 receptor γ chain which is shared by the receptors for IL2, IL4, 
IL7, IL9, IL15, IL21, which are important in the development, differentiation 
and functional maturation of various murine hematopoietic lineages.  The 
incidence of thymoma is much lower, and therefore, lifespan is much longer 
than other immunodeficient strains, allowing studies on chronic disease 
conditions.  Despite several characterized defects in the reconstituted immune 
system and suboptimal reconstitution of parts of the immune system due to 
differences in the cytokine milieu, the human lymphocyte compartment is the 
most consistently and reliably reconstituted.  Therefore, this strain of 
humanized mouse offers an excellent up-to-date system to model EBV 
infection which specifically targets the human B cell compartment and thus 
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allows us to study various immunological, virological and pathophysiological 
aspects of EBV infection and associated lymphoproliferative diseases. 
 
1.6.1 Early mouse models of EBV-associated lymphoproliferative disease 
Earlier mouse models of EBV-associated lymphoproliferative disease were 
based on the injection of peripheral blood mononuclear cells from EBV 
seropositive donors (directly or selected for EBV-immortalized B cells) into 
SCID mice 145 and NOD/SCID mice. 146,147   Systemic lymphoproliferative 
lesions were observed with varying frequency and severity depending on the 
functional activity of individual donor’s T lymphocytes 148.  Development of 
lesions in NOD/SCID mice was later found to be dependent on the presence of 
T lymphocytes and associated factors secreted by them 138.  All those earlier 
mouse models focused on investigating the ability of EBV-transformed B cells 
to form tumors in vivo and the observations were restricted to characterization 
of the tumor lesions which provided little insight into the host-disease 
interaction, host-pathogen interaction, virus-induced pathology and sequence 
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1.6.2 Humanized mouse models of EBV infection and lymphoproliferative 
disease 
The first humanized mouse model of EBV infection and associated 





 mouse strain.  After this pioneer publication, 
many groups have attempted to model the EBV infection and associated 
lymphoproliferative disease with a different focus – the human immune 
response against the virus and associated pathology in a humanized mouse 


















B95-8  Dose-dependent LPD; Ex vivo T cell 
proliferation assay upon stimulation with 








Kappa chain-restricted LPD with latency II 
gene expression pattern  
Islas-
Ohlmayer, 
et al. 150 
NOD/SCID 
- BLT  
Akata  Lesions not well characterized; Increase in 
memory T cells; MHC class I-restricted CTL 








B95-8  Diffuse and nodular LPD with latency II and 
III gene expression pattens; Ongoing SHM  
Cocco, et al. 
152
 
NOG - CB  Akata  Dose-dependent LPD; Increase in memory 
and activated T cells; MHC class I-restricted 
CTL response (ex vivo IFN-γ ELISPOT)  
Yajima, et 
al. 153  
NOG - CB  Akata  Depletion of T cells and CD8
+





A2 -  FL  
?  Systemic LPD; HLA-restricted EBV-specific 
CTL response (Tetramers of LMP2 and 
















Summary of findings  Publications 
NSG-HLA-
A2 -FL  
B95-8  Systemic LPD; HLA-restricted EBV-specific 
CTL response (Tetramers of LMP1 and 
BMLF1); EBV-specific CTL cytotoxicity  
Shultz, et al. 
156
 
NOG - CB Akata EBV-associated hemophagocytic 
lymphohistiocytosis 




Table 3. Summary of published humanized mouse models of EBV 





- Rag2 and interleukin 2 receptor γ chain knockout mouse strain in BALB/c 
background; NOG – NOD-scid IL2Rγc
truncated
; NSG – NOD-scid IL2Rγc
null
; 
NOD/SCID-BLT – bone marrow, liver, thymus transplanted NOD/SCID 
mouse strain; CB – cord blood; FL – fetal liver; LPD – lymphoproliferative 
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1.6.3 Differences in the humanized mouse strains in previous studies 
A number of published reports have appeared in recent years on humanized 
mouse models of EBV infection and associated lymphoproliferative disease 





, NOG, NSG, BLT, etc., and reconstituted with 
isolated human hemopoietic progenitors from different sources, namely adult 
peripheral blood (mobilized from bone marrow), umbilical cord blood, fetal 
liver, etc.  While the humanized mouse technology is still far from perfect, 
researches in the past decade have fine-tuned this system.  Following the 




, NOG, human bone 
marrow, pieces of liver and thymus were transplanted in stages to create the 
BLT mice (Bone marrow, Liver and Thymus-transplanted humanized mice) to 
approximate the thymic education during T lymphocyte development and to 
elicit more robust and more human-like immune responses.  Although BLT 
mice were regarded as a gold standard humanized mouse model (given the 
microenvironment the human immune system developed in), creation of a 
BLT humanized mouse model remains a challenge as transplantation of 
human-derived tissues is technically difficult.  With the advent of NSG mice 
with transgenic human HLA-A2 expression in the thymus, a marginally better 
HLA-restricted EBV-specific T lymphocyte response could be elicited.  
However, a comparison of the published models should be made with extreme 
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caution as the extent of human cell reconstitution and their functionality can 
be very variable. 
 
1.6.4 Differences in virus strains used in previous humanized mouse 
studies 
The EBV virus strains employed in different published reports include the 
prototype B95-8 strain obtained from marmoset leucocytes 158 and the Akata 
strain from Burkitt’s lymphoma cell lines 159.  The intrinsic characteristics of 
the different viral strains have resulted in some significant differences in the in 
vivo effects of EBV infection in humanized mice.  For example, Akata strain 
is very prolific in virus production and the virus induction kinetics is very fast 
when surface immunoglobulins are cross-linked by anti-immunoglobulins 160.  
Recent reports on deep sequencing of Akata strain showed the similarity to 
that isolated from nasopharyngeal carcinomas GD1 161.  Since the intrinsic 
pathogenic potential of the virus strains is very different, we should take 
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1.6.5 Controversy of the published models  
The published literature on humanized mouse models of EBV infection 
unanimously reported some form of immune response against the virus 149,151. 
and Yajima, et al. 153 reported that T lymphocytes isolated from humanized 
infected mice could secrete IFN-γ upon ex vivo stimulation with autologous 
lymphoblastoid cells (human B cells immortalized by EBV infection in vitro).  
In addition, Yajima, et al. 153 reported MHC class I-restricted T cell immune 
responses and a markedly accelerated course of disease with reduced survival 
of infected mice when total T lymphocytes and CD8+ CTLs were depleted.  
Strowig, et al. 155 and Shultz, et al. 156 reported HLA-restricted EBV-specific T 
lymphocyte response and HLA-restricted cytoxicity against EBV-infected 
human B cells.  These observations strongly indicated the hypothetical 
immune response in EBV-infected humanized mice.  These same reports also 
showed florid fatal systemic lymphoproliferative disease and claimed that 
EBV was tumorigenic.  Traggiai, et al. 149 and Yajima, et al. 153 also reported 
that the disease onset and severity was dependent on the infecting virus load.  
However, there was no satisfactory explanation on how EBV infection could 
lead to fatal lymphoproliferative disease if the humanized mice could exert 
robust EBV immune responses.  The effectiveness of these reported T cell 
immune response against the virus and virus-induced pathology is, therefore, 
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1.6.6 Current concepts about the role of human B cells in EBV-associated 
lymphoproliferative diseases based on animal models 
Early experimental mouse models of EBV infection and associated 
lymphoproliferative disorder were established using NOD/SCID mice injected 
with peripheral blood mononuclear cells from EBV seropositive donors 146-148.  
These reports mentioned heterogeneity of the donor cells in terms of disease 
onset and severity and it was postulated to be due to the variation in T cell 
proportion and functionality in different donors.  Depletion of CD3+ human T 
cells and CD8+ human CTLs were also shown to reduce the life span of EBV-
infected mice in NOG mouse model, implying the importance of the lack of T 
cells, more specifically CD8+ CTLs in the pathogenesis of the systemic tumor-
like lesions observed 154.  Veronese, et al. 138 reported a series of cell depletion 
experiments and concluded that T cells and/or the factors secreted by them 
were necessary for tumorigenesis of EBV-infected B cells, at least during the 
tumor initiation step in the human peripheral blood leucocyte-reconstituted 
NOD/SCID mouse model.  Therefore, the importance of the lack of T cell 
immunity has been extensively studied.  However, there is no study to date 
directly addressing the causative role of EBV and EBV-infected human B 
cells in the pathogenesis of EBV-associated lymphoproliferative disease, 
which is mainly a B cell disease.  
 In this study we aimed to develop and employ a humanized mouse 
model for EBV infection using the standard B95-8 virus strain.  This model 
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will be utilized to address the question of whether a true causal relationship 
exists between EBV and tumorigenesis in the context of immunodeficiency-
related lymphoproliferative disease.  Our specific aims are detailed in the next 
section.   
 





Aims and Objectives of the study 
 
Main Aim 1 :  Establishment of the humanized mouse model of EBV 
infection. 
Objective 1: The isolation of hemopoietic progenitors from fetal liver by 
immunomagnetic bead selection 
Objective 2 :  The humanization of mice by intracardiac injection of 
human hemopoietic progenitors into newborn NSG pups 
Objective 3 :  EBV culture using B95-8 cell lines and associated virology 
Objective 4 :   In vivo EBV infection and monitoring of disease activity in 
infected mice 
 
Main Aim 2 :  Characterization of the humanized mouse model. 
Objective 1 :  Weekly peripheral blood analysis - viremia and detailed 
phenotyping of immune cells by multi-parameter flow 
cytometry and multiplex cytokine assay. 
Objective 2 :  Autopsy of the mice at week 12 post-infection or at the time 
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Main Aim 3 :  Analysis of EBV-linked tumorigenesis in vivo 
Objective 1 :  Demonstration of the pivotal role of human B cells in the 
disease pathogenesis by specific B cell depletion using the 
therapeutic antibody - Rituximab  
Objective 2 : Secondary transfer of unfractionated splenocytes into non-
humanized NSG mice and monitoring the disease onset, 
frequency, severity and lifespan (survival analysis) 
Objective 3 :  Secondary transfer of sorted B cells from EBV-infected 
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CHAPTER 2 :  MATERIALS AND METHODS 
2.1 ISOLATION OF HEMOPOIETIC STEM AND PROGENITOR 
CELLS (HSCS) FROM HUMAN FETAL LIVER 
Human fetal tissues were obtained with a written informed consent from the 
mother and utilized in accordance with the guidelines stipulated by the 
Institutional Review Board.  Human hemopoietic progenitors were isolated 
from the human fetal liver dissected from the 14 – 24 week old aborted 
fetuses.  The fetal livers were homogenized into small pieces and digested in 
sterile-filtered collagenase IV solution (2 mg/ml final concentration in 
DMEM) for 15 minutes with interval shaking at 37˚C .  Digested liver 
fragments were passed through the 100 µm cell strainer and washed with 
DMEM.  The single cell preparation thus obtained was incubated in ACK lysis 
buffer (Invitrogen #A10492-01) for 10 – 15 minutes for RBC lysis.  Fetal liver 
cells were then washed twice and resuspended in RoboSep buffer in 2 x 108 
cells per ml density.  Hemopoietic progenitors were isolated using EasySep 
human CD34 positive selection kit (StemCell Technologies #18056) using 
customized fetal liver CD34 positive selection program in the RoboSep 
machine.  Purified CD34+ hemopoietic progenitor cells were frozen in the 
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2.2 ESTABLISHMENT OF THE HUMANIZED MOUSE 
Newborn NOD/SCID/IL2Rγ-/- (NSG) mice were sublethally irradiated by 
gamma radiation.  Frozen human CD34+ fraction of hemopoietic progenitor 
cells isolated from the fetal liver were thawed at 37˚ C  and 2 × 105 CD34+ 
cells were injected into irradiated newborn NSG mice via the intracardiac 
route.  After 10 – 12 weeks, the reconstitution of human cells in the peripheral 
blood of the humanized mice was assessed by flow cytometry using human 
pan-leucocyte marker CD45 and mouse pan-leucocyte marker CD45.1.  The 
human cell reconstitution proportion was calculated as follows: 
𝐑𝐞𝐜𝐨𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐢𝐨𝐧 =  𝐇𝐮𝐦𝐚𝐧 𝐂𝐃𝟒𝟓
𝐇𝐮𝐦𝐚𝐧 𝐂𝐃𝟒𝟓 + 𝐌𝐨𝐮𝐬𝐞 𝐂𝐃𝟒𝟓.𝟏  × 𝟏𝟎𝟎 % 
All animal experiments were conducted according to the guidelines of 
Institutional Animal Care and Use Committee at National University of 
Singapore.   
 
2.3 EPSTEIN-BARR VIRUS CULTURE, VIRUS TITER ASSAY 
AND IN VIVO INFECTION 
EBV was obtained from the virus-producing marmoset leucocyte cell line 
B95-8 which was a kind gift from Prof. Chan So Ha from WHO Immunology 
Center Singapore.  The cells were seeded to the density of one million cells 
per milliliter in RPMI medium supplemented with 10% fetal calf serum and 
100 units of penicillin/100 µg streptomycin per ml and cultured in the 
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incubator at 37˚C and 5% CO2.  After 14 days of culture without changing the 
medium, supernatant was collected, centrifuged, filtered through 0.45 micron 
syringe filter, then aliquoted in 1.5 ml eppendorf tubes and stored in a -80˚C 
freezer until utilization.  The virus titer was assessed by quantitative PCR 
using TaqMan probe complementary to the W repeat region of the EBV 
genome.   
 On the day of infection, the EBV-containing supernatant containing 
was thawed at 37˚C and  2 × 106 viral particles were injected into the 
reconstituted NSG mice through the tail vein.  The infection was monitored by 
weekly plasma viremia measurement by the same qPCR system used for virus 
titer assessment. 
 
2.4 FLOW CYTOMETRIC IMMUNOPHENOTYPING 
Peripheral blood mononuclear cells (PBMCs) or isolated splenocytes were 
washed and resuspended in flow cytometry buffer solution containing 0.2% 
bovine serum albumin and 0.05% sodium azide in PBS.  The cells were then 
stained with different fluorophore-conjugated antibodies at 4˚C for 15 
minutes.  Unbound antibodies were washed away twice.  Stained cells were 
then analyzed in the BD LSRII flow cytometer and the data was analyzed with 
FlowJo software v7.6.4. 
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 To obtain an absolute cell count during weekly peripheral blood 
analysis, a fixed volume of anti-coagulated whole blood was used and the 
plasma was separated by centrifugation.  The cells were treated with ACK 
lysis buffer for RBC lysis, washed and resuspended in 200 µl (0.2 ml) of flow 
cytometry buffer and counted using hemocytometer.  The absolute count 
(cells/ml) was obtained by using the following formula: 
𝐀𝐛𝐬𝐨𝐥𝐮𝐭𝐞 𝐜𝐨𝐮𝐧𝐭 = 𝐂𝐞𝐥𝐥 𝐜𝐨𝐮𝐧𝐭 × 𝟎.𝟐 × 𝟏𝟎𝟎𝟎
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Table 4. Fluorochrome-conjugated anti-human antibodies used for 
flow cytometry analysis.  The antibodies and respective fluorophore 
conjugates used in this study are listed.  Antibodies were purchased from 
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2.5 HISTOPATHOLOGY 
Tissues and organs harvested from the mice were either frozen in OCT 
medium and stored in -80˚C freezer or preserved in 10% neutral buffered 
formalin, processed and embedded in paraffin.  Tissue sections were cut to 5 
micron thickness and stained with hematoxylin and eosin, immunofluorescent 
stains or immunohistochemistry respectively.  Immunohistochemistry stains 
were visualized with Third generation IHC detection kit (Invitrogen #85-
9073).  Stained slides were scanned using Carl Zeiss MIRAX MIDI slide 
scanner and analyzed using MIRAX viewer image viewing software v1.12. 
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2.6 VIREMIA ASSAY 
Plasma was isolated from the peripheral blood by centrifugation and stored in 
-20˚C until analysis.  Plasma samples were thawed at room temperature and 
viral DNA was extracted using QiaAmp MinElute viral DNA kit (Qiagen 
#57704).  The absolute virus copy number was detected by TaqMan probe 
complementary to BamHI-W region W-67T [5’-(FAM) 
CACACACTACACACACCCACCCGTCTC (TAMRA)-3’], primers W-44F 
[5’-CCCAACACTCCACCACACC-3’] and W-119R [5’-
TCTTAGGAGCTGTCCGAGGG-3’] 162, using quantitative PCR master mix 
(Applied Biosystems #4304437).   
  
Component Vol. (µl) Final conc. 
TaqMan Uni Mix (2x) 12.5 1x 
Forward Primer (144F) (10 µM) 0.75 300nM 
Reverse Primer (119R) (10 µM) 0.75 300nM 
Probe (5uM) 1 200nM 
Total (to be aliqouted) 15  
DNA sample 10 10-100ng 
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A standard curve was run in parallel in duplicate in the same 96-well plate 
using DNA extracted from EBV-positive cell line Namalwa (ATCC CRL-
1432)163.  Namalwa is a diploid cell line 164 which contains two integrated 
viral genomes per cell 165.  A conversion factor of 6.6 pg of DNA/diploid cell 
was used for copy number calculation 166.  Tenfold serial dilutions of 
Namalwa DNA were prepared in concentrations of 250 ng/µl to 0.0025 ng/µl 
and 4 µl (+ 6 µl of distilled water) was used in each duplicated reaction to 
obtain the standard DNA of 1000 ng to 0.01 ng, equivalent to 3 × 105 copies 
to 3 copies of viral DNA. 
Amplification signal was detected by BioRad CFX96 real time qPCR 
machine and the data was analyzed using BioRad CFX manager software 
version 3.0.  The standard curve was plotted as in Figure 4.   
Concentration of circulating cell-free plasma EBV DNA was 
calculated with the following formula and expressed as copies/ml plasma. 
 
𝐂 = 𝐐 × 𝐕𝐨𝐥.  𝐨𝐟 𝐞𝐥𝐮𝐭𝐞𝐝 𝐯𝐃𝐍𝐀 (𝟐𝟎 µ𝐥)
𝐕𝐨𝐥.  𝐮𝐬𝐞𝐝 𝐟𝐨𝐫 𝐏𝐂𝐑 (𝟏𝟎 µ𝐥)  × 𝟏𝐕𝐨𝐥.𝐨𝐟 𝐩𝐥𝐚𝐬𝐦𝐚 𝐞𝐱𝐭𝐫𝐚𝐜𝐭𝐞𝐝  
 
C is the target concentration (copies/ml) and Q is the target quantity (copies) 
















Figure 4. EBV viremia qPCR standard curves.  (A) Amplification 
curves of standard ten-fold dilution of Namalwa DNA preparation in triplicate.  
(B)  A standard curve obtained from amplification of serial ten-fold dilutions 
of Namalwa DNA which contains 3 – 300,000 EBV virus copies. 
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2.7 MULTIPLEX CYTOKINE ASSAY 
Multiplex cytokine assay was performed by BioRad 17-plex human cytokine 
assay system (BioRad #M50-00031YV) according to the manufacturer’s 
protocol.  Plasma was separated by centrifugation and stored in -20˚C.  On the 
day of analysis, plasma samples were thawed at room temperature and diluted 
in four-fold in sample diluents supplied by the manufacturer.  30 µl of plasma 
was used for analysis.  Cytokine standards were reconstituted in standard 
diluents and serial four-fold diluted samples were prepared.  The plate was 
pre-wetted in assay buffer.  Diluted multiplex beads solution was prepared and 
aliquoted into individual wells of the provided 96-well plate.  After washing, 
diluted standard and sample preparations were aliquoted in duplicates and 
incubated at room temperature with shaking for 60 min.  Next, the plate was 
washed and antibody detection solution was prepared, mixed with the samples 
and incubated at room temperature with shaking for 30 min.  The excess 
unbound antibodies were then washed off the plate.  Streptavidin-PE solution 
was prepared and incubated for 10 min.  The plate was then washed and the 
samples were resuspended in the assay buffer and read in the Bioplex 
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2.8 TREATMENT OF EBV-INFECTED MICE WITH RITUXIMAB 
Rituximab (Mabthera, Roche) was a kind gift from A/P Chng Wee Joo from 
Department of Hematology and Cancer Science Institute.  Working solution of 
1 µg/µl was prepared from the stock solution (10 mg/ml) by diluting in sterile 
normal saline and injected at a dose of 1 µg/g body weight intravenously via 
the tail vein.  Treatment of infected and control mice was started from the 
sixth week post-infection.  Untreated mice were injected with an equal volume 
of sterile normal saline.  A total of six doses were injected weekly and the 
peripheral blood was analyzed 48 hours after treatment.    
 
2.9 SECONDARY ADOPTIVE TRANSFER TUMOR MODEL 
Single cell suspension of splenocytes was prepared from the spleens of both 
infected and uninfected mice.  For preliminary experiments, unfractionated 
splenocytes were freshly injected intraperitoneally into 8 – 10 week old un-
preconditioned (i.e., no myeloablative procedure such as sublethal irradiation 
was administered) adult male NSG mice.  For subsequent experiments to 
confirm the tumorigenicity of human B cells in the primary mice, splenocytes 
were sorted using human B cell CD19 magnetic beads positive selection kit 
(Stem Cell Technologies #18054) and injected intravenously into 8 - 10 week 
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2.10 STATISTICAL ANALYSIS 
Statistical analysis was performed using Microsoft Excel 2007 and GraphPad 
Prism 5 software.  Student t test, ANOVA and Kaplan-Meier survival curve 
analyses were performed where appropriate and the statistical significance 
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CHAPTER 3 :  RESULTS AND INTERPRETATION 
3.1 ESTABLISHMENT OF THE HUMANIZED MOUSE MODEL  
3.1.1 Experimental scheme for development of a humanized mouse model 
of EBV infection 
 
Figure 5. Experimental scheme of the development of a humanized 
mouse model of EBV infection.  Hemopoietic progenitor cells were isolated 
from human fetal liver by immunomagnetic bead isolation and injected into 
newborn NSG pups via intracardiac route.  Human cell reconstitution was 
assessed by flow cytometry eight to twelve weeks later.  Humanized mice 
were infected with EBV supernatant via intravenous route.  Infected mice 
were then monitored for signs of disease and a detailed analysis of 
clinicopathological, virological and immunological features of 
lymphoproliferative disease was performed.  
 
In this project, we used the NSG strain of mice which was shown to be 
relatively simple to humanize and to have a good degree of human 
hemopoietic system engraftment.  The source of hemopoietic progenitor cells 
was human fetal liver as the yield of progenitor cells after immunomagnetic 
bead isolation from the fetal liver was significantly higher compared to that 
obtained from human umbilical cord blood.  We adopted the intracardiac route 
of injection to reconstitute sublethally irradiated newborn NSG pups as 
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reported by Shultz, et al. 143.  We used the prototype B95-8 strain to infect the 
humanized mice as the whole genome sequence was available and the virus 
strain well characterized. 
 
3.1.2 Isolation of hemopoietic progenitor cells from the human fetal liver 
Hemopoietic stem cells (HSCs) were found in bone marrow 167, umbilical cord 
blood 168, fetal liver 169, and peripheral blood after mobilization with GM-CSF 
170,171.  A true HSC must be able to self-renew and differentiate into different 
lineages of the hemopoietic system 172.  The gold standard of assessment of 
these two properties was reconstitution of the human hemopoietic system in 
SCID mice pre-conditioned with myeloablative treatment such as sublethal 
irradiation 173.  Long-term SCID-repopulating cells are regarded as true HSCs.  
The bone marrow cells positive for CD34 were shown to be capable of 
hemopoietic reconstitution in recipients who received myeloablative 
therapy174-176.  The observation that CD34+ cells were identified in recipients 
of CD34- cells has raised the possibility of a more primitive hemopoietic stem 
cell 177, which was identified to be CD133 178,179.  However, CD34 is still 
widely used as a marker for hemopoietic progenitor cells for most purposes.  
We assessed the HSC content of the fetal liver using both CD34 and CD133. 
The source of hemopoietic progenitor cells we used to reconstitute the 
NSG mice was from fetal liver from aborted normal fetuses of fifteen to 
twenty four weeks gestational age.  After dissection of fetal liver, single cell 
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suspension was prepared and CD34+ population was enriched by 
immunomagnetic bead isolation.  Fractionated cells were stained with the 
hemopoietic stem cell marker CD133, hemopoietic progenitor cell marker 
CD34 and pan-leucocyte marker CD45 and the percentage of hemopoietic 
progenitor was assessed by flow cytometry.  Both CD34+ and CD133+ 
hemopoietic progenitor cells were enriched by CD34 immunomagnetic bead 
isolation of cord blood and fetal liver cells when positive fraction cells were 
compared with the cells before isolation (21% vs. 88% for CD34+ cells; 2% 
vs. 8% for CD133+ cells; and 2% vs. 8% for CD34+CD133+ hemopoietic 
progenitor cells).  See Figure 6.  The positive fraction which contained CD34+ 
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Figure 6. Assessment of purity of CD34 immunomagnetic bead 
isolation of hemopoietic progenitor cells from a human fetal liver.  Human 
pan-leucocyte marker CD45 and human hemopoietic stem and progenitor cell 
markers CD133 and CD34 were used to assess the purity of sorted 
hemopoietic progenitor cells.  Positive fractions were at least four fold 
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3.1.3 In vivo infection of the humanized mouse model with Epstein-Barr 
Virus 
As presented above, we enriched fetal liver mononuclear cells for CD34+ 
hemopoietic progenitors and reconstituted the irradiated mice with 𝟐 × 𝟏𝟎𝟓  
CD34+ cells.  After eight to twelve weeks post-reconstitution, peripheral blood 
chimerism was checked by flow cytometry using the human pan-leucocyte 
marker CD45 and mouse pan-leucocyte marker CD45.1.  Reconstitution 
proportion and percentages of lymphoid lineage cells in an average batch of 
mice were summarized in Figure 7 and Table 6.   
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Figure 7. Assessment of the reconstitution of humanized mice 10 
weeks after intracardiac injection of CD34+ hemopoietic progenitor cells.  
Human CD45 and mouse CD45.1 were gated on DAPI-negative live cells; 
human B cells and T cells were gated on human CD45; and CD4+ T cells and 
CD8+ T cells were gated on CD3+ human T cells.  The lower panel is a 
quantitative representation of a batch of humanized mice at week 10 post-
reconstitution, showing the percentage distribution of human lymphocyte 
lineages and the B cell:T cell and CD8:CD4 ratios.  Horizontal lines represent 
mean values.  
 
 
Table 6. Quantitative representation of reconstitution and lymphoid 
lineage of an average batch of humanized mice.  The average reconstitution 
proportion was typically 65% in an average batch of humanized mice at ten to 
twelve weeks post-reconstitution.  B lymphocyte reconstitution was the same 
as or higher than that of T lymphocytes and the percentage of CD4+ T cells 
was more than that of CD8+ T cells with the CD8:CD4 ratio of 0.5.  
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Typically more than 90% of the reconstituted mice achieved more than 
20% of human cells in the peripheral blood so this was set as a threshold level 
of reconstitution for further experimentation.  The mice were stratified 
according to the reconstitution proportion and assigned so that the 
experimental and control groups had approximately the same average total 
overall human cell reconstitution and B cell percentages.  Humanized mice 
were then infected with EBV supernatant at a dose of 𝟐 × 𝟏𝟎𝟔 virus particles 
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3.2 CHARACTERIZATION OF THE HUMANIZED MOUSE 
MODEL OF EBV INFECTION 
Experimental mice were monitored daily for general well-being, health status 
and signs of disease such as hunched back posture, poor grooming, poor 
mobility, poor feeding and weight loss (the body weight was measured at least 
three times a week).  Peripheral blood was drawn from the facial vein weekly 
for further analysis.  The plasma portion of the whole blood was collected for 
measurement of viremia by qPCR and the cellular component for flow 
cytometric study of human immune responses against the EBV infection.  
The infected mice started to show signs of disease as early as the sixth 
week post-infection and the majority became terminally ill by the twelfth 
week post-infection.  Terminally ill mice were euthanized and the spleen, the 
bone marrow, the liver, the lungs and the kidneys were harvested for flow 
cytometric and histopathological analysis.  More than two thirds of the 
infected mice showed general signs of disease activity, body weight loss as 
shown in Figure 8A and plasma viremia as shown in Figure 8B.  
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Figure 8. Monitoring infected mice by measurement of body weight 
and weekly plasma viremia by qPCR.  (A) Percentage change in body 
weight of humanized infected mice was represented by black line and that of 
control humanized uninfected mice by grey line.  (B) Plasma viremia of 
humanized infected mice (n=4) of a representative batch was shown.  Negative 
threshold was set by the background signal from humanized uninfected mice 
(n=4) and shown by dotted line. 
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As shown in Figure 8B, weekly plasma viremia peaked at the fourth week 
post-infection with a fluctuation in viremia (with small peaks) around the 
ninth week post-infection.  The initial undetectable levels of viremia, 
combined with the peak effect and the subsequent fluctuation are consistent 
with active viral replication after the initial virus clearance.  This is opposed to 
residual viral particles found after the initial redistribution from the injection 
site into the circulation.  In this case, the viremia levels would decline steadily 
with time.  The negative threshold indicated by the dotted line in Figure 8B 
was set by the background signals picked up in the plasma samples of 
humanized uninfected mice.  Viremia was not detected in non-humanized 
infected NSG mice. 
 The clinical manifestation of disease, in terms of gross external 
features, general signs of disease (hunched back posture, poor grooming, 
limited mobility and feeding, etc.) and viremia pattern, was specific to 
humanized infected mice as non-humanized infected mice did not show any 
such manifestations, demonstrating that the EBV infection was specific to the 
human cells and not the mouse cells.  Furthermore, humanized uninfected 
mice did not show any clinical signs of disease nor significant viremia and the 
life span was comparable to non-humanized uninfected NSG mice for the 
course of the experiment, indicating that the human hemopoietic progenitor 
cells used for reconstitution were not pre-exposed to EBV.  Therefore, non-
humanized infected and humanized uninfected control groups confirmed that 
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the disease manifestation was due to EBV infection in the presence of the 
human hematoimmune system.  In subsequent sets of experiments where we 
studied the human immune response and EBV biology, we compared 
humanized infected and humanized uninfected mice groups. 
The viremia pattern observed in the humanized infected mice 
suggested an initial incubation period, an outburst of viral particles, and 
subsequent latent period and periodic low level reactivation spikes.  The 
pattern and sequence of viremia is similar to that in human infection in which 
there is an initial incubation period of several weeks; viral replication peaks 
rapidly and is then controlled by the competent immune system; followed by 
clinically and virologically silent latent period with periodic low level 
reactivation, characteristic of human herpesviruses.  However, unlike human 
beings, the humanized infected mice did not seem to be able to efficiently 
control periodic reactivation suggested by the gradually rising trend of virus 
titer with each reactivation spike, eventually followed by the demise of the 
mice at week 12 post-infection.  Nevertheless, our mouse model replicated 
most of the virological features of the human EBV infection, namely the 
clinical and virological latency with periodic reactivation, and mimicked the 
natural course of EBV life cycle in humans, portraying acute as well as latent 
infection.   
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In addition, we also investigated the human immune responses in 
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Figure 9. Human immune cell response against EBV infection.  The 
percentages (A, C, E, G, I) and absolute counts (B, D, F, H, J, K) of various 
human lymphoid cell compartments obtained by weekly peripheral blood flow 
cytometry were shown.  Black lines represent humanized infected mice and 
grey lines represent humanized uninfected mice.  Both CD45+ human 
leucocyte percentages (A) and absolute counts (B) were significantly higher in 
infected mice.  Although the absolute human B lymphocyte counts (D) were 
significantly higher at the fourth and fifth week of infection, the overall trend 
was not significantly different from that of uninfected mice (C, D).  Absolute 
human T lymphocyte counts were significantly higher in infected mice (F) but 
the percentages of T cells were comparable with the uninfected mice (E).  The 
percentage of human CD4+ helper T lymphocytes was significantly lower (G) 
and that of human CD8+ cytotoxic T lymphocytes higher in infected mice (I).  
The absolute counts of both helper and cytotoxic T lymphocytes were 
markedly higher in infected mice (H, J).  The ratio of CD8+ T cells to CD4+ T 
cells in the peripheral blood was markedly higher in infected mice throughout 
the course of infection (K).  Data shown were from a representative batch of 
mice – infected mice (n=6) and uninfected mice (n=4).  Two way ANOVA 
test was performed and statistical significance (p value < 0.05) was presented 
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The human immune response against EBV is primarily the function of CTLs 
and is aimed at controlling the massive expansion of EBV-infected 
transformed B cells.  We investigated the cellular immune response against 
EBV infection in the humanized mouse and found several features that closely 
parallel those of EBV-infected human counterparts.  First we looked into the 
changes in the proportion and the absolute numbers of total human leucocytes, 
B cells, T cells, CD4+ helper T cells and CD8+ cytotoxic T cells in the 
peripheral blood by multicolor flow cytometry and the quantitative results are 
summarized in Figure 9 above.   
Compared to humanized uninfected mice, infected mice had 
significantly higher absolute cell counts in their total human leucocyte 
population, accompanied by significantly higher total human T cell, helper T 
cell and CTL subsets plus an increase in their CD8:CD4 ratio.  Although the B 
cell population was significantly higher at early time points post-infection, 
comparison of the overall time series with uninfected mice did not reach a 
statistical significance.  The plots showing the percentages of immune cells 
depict the intrinsic characteristics of the NSG mice – the decline in the B cell 
population and the increase in the T cell population as the mice age.  Although 
there were no significant differences in the percentages of the B and T cell 
populations, the significant differences in the absolute counts suggest that the 
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An integrative interpretation of the changes highlighted above in 
human lymphocyte subsets together with the viremia pattern shown in    
Figure 8 revealed many interesting features of the human immune response 
against EBV infection in humanized mice which may replicate the cellular 
response of their human counterparts.  In the early stage of EBV infection in 
humanized mice, we saw an increase in the B cell counts which implied EBV-
induced B cell transformation and proliferation.  Lytic viral replication with 
peak viremia at the fourth week post-infection was followed by massive 
outburst of viral particles, resulting in more B cells being transformed and 
thereby pushing the B cell proliferation curve to the peak one week later at the 
fifth week post-infection (see Figure 9D).  The EBV-induced B cell outgrowth 
was evident from the fact that B cell absolute counts increased gradually from 
the beginning of the analysis period at the second week post-infection and well 
before the virus started to replicate.  B cell numbers continue to increase up 
until the fifth week (one week after the viremia peak). 
 The outgrowth of EBV-infected B cells was followed by a parallel 
increase in the absolute number of total T cells, helper T cells and CTLs and a 
significantly higher CD8:CD4 ratio in infected mice at the fifth week post-
infection.  The trend of change in the absolute number of peripheral blood T 
cells and subsets was closely parallel to that of viremia, suggesting that there 
may be an anti-viral immune response predominantly contributed by CD8+ 
CTLs.  However, there remains an alternative explanation:  the increase in 
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CTL counts towards the end of the experimental course was due to continuous 
effort of this T cell subset to suppress the ongoing selection of EBV-
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3.2.3 Peripheral blood activation marker profile 
 
 
Figure 10. Activation marker profile of human immune cell response 
against EBV infection.  Percentages (A, C) and absolute counts (B, D) of 
expression levels of activation marker CD95 on B cells and HLA-DR on T 
cells in infected and uninfected mice were compared.  CD95+ human B cell 
and HLA-DR+ human T cell populations were gated on CD19+ human B cells 
and CD3+ human T cells respectively.  Black lines represent infected mice and 
grey lines humanized uninfected controls.  Although the percentages of CD95+ 
B lymphocytes (A) and HLA-DR+ T lymphocytes (C) were not different in 
infected and uninfected mice, the absolute counts of CD95+ B lymphocytes 
(B) were significantly higher in infected mice.  The absolute HLA-DR+ T 
lymphocyte counts (D) followed the same trend in early time points but the 
comparison of the overall trends did not reach statistical significance.  Data 
shown were from a representative batch of mice – infected mice (n=6) and 
uninfected mice (n=4).  Two way ANOVA test was performed and statistical 
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As shown in Figure 10, expression of activation markers augmented the 
evidence that an immune response engendered by EBV is taking place in the 
infected mice.  Fas receptor CD95 is expressed on the surface of virally 
infected cells to elicit the CTL response through engagement with Fas ligand 
(FasL) on CTLs, resulting in the apoptotic death of CD95-expressing cells.  It 
is a way to eliminate infected cells from the system.   
The population of human B cells expressing the death receptor (CD95) 
was found to be significantly higher in infected mice compared to uninfected 
mice, which suggests that they may be potential targets for Fas-mediated 
apoptotic cell death.  Falk, et al. 180 observed that Fas receptor was expressed 
only in lymphoblastoid cells and EBV-positive Burkitt’s lymphoma cells in 
prolonged culture but not in EBV-negative Burkitt’s lymphoma cells.  This 
finding suggested that Fas might be useful as an indirect marker of EBV 
infection.  Therefore, a significantly higher number of Fas-positive human B 
cells in infected mice indirectly suggest the presence of EBV in the human B 
cell compartment.  
We also investigated the expression of HLA-DR on human T cells as a 
marker for activation.  HLA-DR sensitizes T cells to the effects of IL2-
induced proliferative response 181.  HLA-DR is a late activation marker for T 
cells in contrast to CD69 the expression of which is early and transient182.  In 
the case of a chronic latent disease like EBV infection, persistent T cell 
activation is expected to occur throughout the course of infection.  As shown 
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in Figure 10D, HLA-DR positive T cell counts showed a fluctuating trend 
with peaks closely following those of plasma viremia by one week (Figure 
8B).  Although the overall trend of the HLA-DR+ T lymphocyte counts was 
not statistically significant, the peak levels at the fifth week post-infection 
were significantly higher compared to the corresponding levels seen in 
uninfected mice, showing that human T cells in infected mice were indeed 
activated by the virus infection. 
As shown in Figure 10A and C, percentages of the B and T cells with 
respective activation markers were not much different in infected and 
uninfected mice groups while absolute cell counts (Figure 10B and D) were 
clearly higher in infected mice.  This finding implies that there is a functioning 
intrinsic homeostatic mechanism which maintains activated lymphocytes at a 
certain proportion of the overall T cell population so as to control the 
accumulation of activated cells and to prevent collateral damage induced by 
them in the presence of chronic immunologic stimulus like EBV.  It would be 
very interesting to study how this homeostatic mechanism functions and our 
mouse model can be used in this context. 
To sum up the experimental findings on weekly peripheral blood 
analyses, we present evidence that the human immune system in EBV-infected 
mice does mount an immune response against the virus although the 
functionality of the actual cytotoxic mechanisms could not be confirmed. 
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 The virological and immunological features of EBV infection detailed 
so far in the peripheral blood of humanized infected mice were subjected to a 
more detailed analysis of the splenic immune cell compartments and 
histopathological examination of the affected organs.  We present our findings 
in the following chapter.  
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3.2.4 Gross pathological examination of fatal systemic lymphoproliferative 
lesions in EBV-infected humanized mice. 
 
Figure 11. Autopsy of the humanized EBV-infected mice.  
Splenomegaly is a consistent feature in EBV-infected mice, accompanied by 
multiple mass lesions in the spleen and the liver at the twelfth week post-
infection.  Quantitative bar chart on the right panel showed that spleens of the 
infected mice were significantly larger and had more cells compared to those 
of uninfected mice.  Black bars represent humanized infected mice and white 
bars, humanized uninfected control mice. 
 
Around week twelve post-infection, infected mice had significant weight loss 
and showed signs of terminal disease (lethargy, poor ambulation, poor 
feeding, poor grooming).  On autopsy, the most significant finding was 
massive splenomegaly, accompanied, in most cases, by multiple mass lesions 
in the spleen, the liver and occasionally the lungs and the kidneys (Figure 11).  
Cut sections of the spleens with mass lesions revealed firm, solid, dense and 
fleshy tissue.  Lymph nodes were enlarged only in a few mice and 
lymphadenopathy was not a common feature in our mouse model.    Autopsy 
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findings on gross pathological examination of the mice were consistent with 
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3.2.5 Histopathological study of the systemic lesions 
 
    
Figure 12. Histopathological examination of infected mice tissues.  (A)  
Hematoxylin-Eosin staining of systemic lesions showed profuse infiltration of 
human cells (large arrows) in the spleen, liver and lung with destruction of 
normal tissue architecture.  Frequent mitotic patterns were noted in the 
infiltrated areas. (thin arrows)  A few Reed-Sternberg-like giant cells were 
also noted. (open arrows)  (B)  Immunohistochemistry staining of infected 
mice spleen for latent EBV protein LMP1 and human B lymphocyte marker 
CD20, showing that infected spleens were infiltrated by EBV-infected human 
B lymphocytes.  Humanized uninfected mice did not stain for LMP1 showing 
specificity of the antibody.  Splenic human B cells did not express the 
germinal center centroblast-specific marker, CD77. 
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A histopathological examination was performed on the systemic lesions to 
investigate the nature of the lesions.  Hematoxylin and Eosin staining of the 
spleen, liver and lungs showed heavy infiltration of the parenchyma with 
mononuclear cells, disrupting normal tissue architecture as compared with 
control humanized uninfected mice (large arrows in Figure 12A).  Infiltration 
was noted in peri-vascular regions  (perivascular cuffing) in the lungs.  Diffuse 
cellular infiltration was observed in the hepatic parenchyma with patchy 
necrotic areas in the liver.  Frequent and bizarre mitotic figures were also 
found in the infiltrated areas. (thin arrows in Figure 12A, lower panel)  A few 
Reed-Sternberg-like giant cells (large cells with multiple nuclei resembling 
“owl’s eyes” with a perinuclear halo) were also noted in the affected organs. 
(open arrows in Figure 12A, lower panel) 
Immunohistochemistry staining of the spleen sections showed positive 
staining of the human B lymphocyte marker CD20, in the infiltrated areas and 
a more scattered pattern of LMP1 staining (Figure 12B), confirming that the 
infiltrated cells were indeed human B lymphocytes and that there was 
evidence of EBV within the affected tissues.  Latent membrane protein 1 
(LMP1), one of the putative EBV oncogenes shown to have cell transforming 
properties 71, is expressed in latency II and III patterns of latent EBV infection.  
Expression of LMP1 is not compatible with lytic EBV infection 183, further 
confirming that the EBV established latent infection in our mouse model.  
Human B cells in the spleens of EBV-infected mice, however, did not express 
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CD77, which is a specific marker for the centroblast stage of germinal center 
maturation 184.  CD77 was also reported to be expressed in Burkitt’s 
lymphoma and post-transplant lymphomas 185,186. 
The widespread systemic nature of the lesions and histopathological 
features indicated a fatal lymphoproliferative disease, highly suggestive of 
malignant lymphoid proliferation.  The lesions were composed of EBV-
infected human B cells but the maturation stage of the B cells could not be 
determined.  Negative CD77 staining showed that human B cells in the 
affected organs were not centroblasts and might be at the naïve pre-
centroblastic stage or at the post-germinal center mature B cell stage.  A more 
detailed analysis of the nature of immune cells in the affected organs was 
performed by multicolor flow cytometry and described in the following 
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3.2.6 Significant T cell expansion with higher CD8:CD4 ratios in the 
spleens of infected mice 
 
 
Figure 13. Flow cytometric analysis of host immune response against 
EBV infection – splenic lymphocyte lineages.  (A)  Flow cytometry plots of 
a representative batch are shown in the left panel and the quantitative data in 
the right panel.  Human and mouse leucocyte populations were gated on live 
cells (DAPI-); CD19+ B cells and CD3+ T cells were gated on human CD45; 
and CD4+ and CD8+ T cell subsets were gated on T cells.  (B)  Black bars in 
the quantitative bar chart represent infected mice and white bars, uninfected 
mice.  Infected mice had significantly higher CD45+ human leucocyte and 
total T cell percentages and CD8:CD4 ratio and a significantly lower human B 
cell percentage.  Data shown were from a representative batch of mice.  
Student t-test was performed and the statistical significance (p value < 0.05) 
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To understand the human immune response against EBV in humanized mice, 
we did a thorough analysis of the splenocytes using multicolor flow 
cytometry.  As shown in Figure 13, enlarged spleens of infected mice were 
infiltrated with human T lymphocytes which populated 80% of total 
splenocytes while the average human cell proportion in uninfected humanized 
mice of the same age was maintained around 30%.  Similar to the trend of 
immune cells in the peripheral blood, the majority of the cells were human T 
cells, more specifically CD8+ CTLs.  The ratio of CD8 to CD4 was 
significantly increased in infected mice spleens, again highlighting the CTL 
response engendered by EBV infection.  
The human B cell percentage in infected mice was significantly lower 
compared to that of uninfected mice, suggesting that EBV-infected B cells 
were eliminated by CD8+ CTLs in the spleen of infected mice.  This finding 
combined with the observation that the absolute cell count of CD95+ B cell 
population was shown to be higher in the peripheral blood of infected mice 
(see Figure 10B), suggested that human B cells in infected mice were tagged 
to be eliminated by CD95-mediated apoptosis.  We investigated the activation 
marker profile of splenocytes in the next section.  
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Figure 14. Expression of activation markers on splenic lymphocytes.  
The flow cytometry plots on the left panel show expression of the activation 
markers CD95 (A) and HLA-DR (B) on splenic B and T cells, gated on human 
CD45 population.  The corresponding quantitative data are shown on the right 
panel.  Black bars in the quantitative bar chart represent infected mice and 
grey bars, uninfected mice.  Infected mice had a significantly higher 
expression of both CD95 and HLA-DR on human B cells but the expression of 
HLA-DR on B and T cells was not significantly different.  Data shown were 
from a representative batch of mice.  Student t-test was performed and the 
statistical significance (p value < 0.05) presented by an asterisk *. 
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We decided to look deeper into the activation status of human B and T cells in 
the spleens of infected mice by expression of the activation markers CD95 and 
HLA-DR (Figure 14).  Activation marker positive cell populations followed 
the same trend as that found in the peripheral blood.  The percentages of CD95 
expressing B and T cells were significantly higher in infected mice compared 
to uninfected controls.  This supported our hypothesis that human B cells in 
EBV-infected mice were tagged to be eliminated by CD95 (Fas)-mediated 
apoptosis.   
EBV has an interesting interaction with the human immune system.  
The virus has been shown to induce Fas in T lymphocytes and Fas ligand in B 
cells 187.  This results in the induction of apoptosis of the CTLs by the infected 
B cells which express Fas ligand.  This is contrary to the current notion that 
CTLs induce programmed cell death in the virus-infected host cells.  
Expression of Fas (CD95) on T cells is postulated to be important in the 
homeostasis of activated CTLs targeting the virus-infected cells.  It may also 
be an important immune evasion mechanism adopted by EBV to sustain latent 
persistence in the host cells.  Although we did not analyze Fas ligand 
expression in B cells, our mouse model clearly showed a significantly higher 
population of CD95 expressing T cells as part of the anti-EBV response.     
The percentages of HLA-DR expressing T cells were comparable 
although the absolute counts were higher in infected mice due to a higher 
proportion of human cells.  Previous reports on HLA-DR-positive human T 
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cell response showed a marked increase in the HLA-DR+ activated CTLs153,155 
but we should be careful of comparing our results with those reported because 
the virus strain and the unit of infecting virus titer used in the two studies were 
different.   
As discussed in the peripheral blood analysis section, HLA-DR 
expression on T cells represents an activated T cell phenotype.  At the twelfth 
week post-infection, there was no significant difference between the HLA-
DR+ T cell populations of infected and uninfected mice in the spleen.  Since 
we have shown that T cells were activated in the peripheral blood, we assumed 
that activated T cells in the spleen were cleared by Fas-mediated apoptosis 
induced by EBV-infected B cells as reported by Tanner and Alfieri 187  but we 
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 3.2.8 Marked expansion of CCR5+ Th1 cells in infected mice with poor 
memory T cell development 
T lymphocytes constituted the majority of splenocytes and we have 
accumulated some evidence of a CTL response in the peripheral blood 
throughout the course of infection.  Therefore, we decided to look deeper into 
different T cell subsets in the spleen and the data is summarized in Figure 15.   
 
Figure 15. Flow cytometric analysis of splenic T cell and memory cell 
subsets.  (A)  The flow cytometry plots on the left panel show expression of 
cell surface markers characteristic of Th1 cells (CCR5), naïve T cells 
(CD45RO) and memory cell subset marker (CCR7), gated on human CD45 
population.  Th1 cells – CCR5+; naïve T cells – CD3+CD45RO-; antigen-
experienced memory T cells – CD3+CD45RO+; central memory cells – 
CD45RO+CCR7+; effector memory cells – CD45RO+CCR7-.  (B-D)  The 
corresponding quantitative data of the percentages of respective T cell subsets 
are shown on the lower panel.  Black bars in the quantitative bar chart 
represent infected mice and white bars, uninfected mice.  Infected mice had a 
significantly higher expression of CCR5+ cells (C) but the memory cell subsets 
were comparable between infected and uninfected mice (B, D).  Data shown 
were from a representative batch of mice.  Student t-test was performed and 
the statistical significance (p value < 0.05) presented by an asterisk *. 
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There was a significant increase in Th1 cells (based on CCR5 expression) 
reflecting the important role of Th1 cells in the immune response against 
EBV.  Traditionally, Th1 and Th2 subsets were differentiated by the specific 
set of cytokines they produce but according to Loetscher, et al. 188, CCR5+ was 
preferentially expressed in T cells which secrete a Th1 pattern of cytokines.  
Therefore, CCR5 was used as a surrogate marker for Th1 cells which can be 
assayed simply by surface staining using flow cytometry. 
In view of the immune response in the peripheral blood and the 
increase in the Th1 population in the spleen, we also studied immunological 
memory.  In 1999, Sallusto, et al. 189 described different memory cell subsets 
using a combination of markers.  We adopted this strategy to study different 
memory cell subsets using a combination of CD45RO (a marker of antigen-
experienced lymphocytes) and CCR7 (a lymph node homing marker).  Gated 
on human CD45 population, CD45RO+CCR7+ population were regarded as 
central memory cells; CD45RO+CCR7- population was regarded as effector 
memory cells; and CD45RO-CCR7+ as naïve lymphocytes. 
As shown in Figure 15, there was no difference in various memory T 
cell compartments as the percentages of CD45RO+ memory T cell, 
CD45RO+CCR7+ central memory T cells and CD45RO+CCR7- peripheral 
memory T cells were the same in infected and uninfected mice, suggesting 
that there were defects in development of T cell memory in humanized mice.  
Several factors might contribute, namely lack of an optimal cytokine milieu; 
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absence or non-functional expression of molecular factors required for cellular 
interactions during the development of the immune response; or intrinsic 
functional deficits in the immune cells developed in the mouse bone marrow 
microenvironment and education in the mouse thymus for human T 
lymphocyte development. 
 Our experimental findings regarding the immune response in infected 
mice showed some evidence of an antiviral immune response including the 
involvement of the Th1 arm of adaptive immunity at the same time 
highlighted some defects in the development of an optimal immune response 
and immunological memory. 
 Our findings on the human immune response discussed so far 
suggested two important reasons accounting for the cause of death of the 
infected mice.  The first and a more plausible reason is that the immune 
response mediated by CTLs was not sufficient or strong enough to control the 
virus and associated pathology.  The second possible reason which might 
contribute to the death of the infected mice was that CTLs themselves induced 
host injury during the futile attempt to clear the virus-infected cells resulting in 
non-specific massive T cell activation with hypercytokinemia.  In short, we 
hypothesize that ‘functional immaturity’ of the immune response or ‘non-
specific’ T cell activation with cytokine storm might contribute to the death of 
the infected mice.     
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  Previous studies showed that EBV-specific T cells constituted a 
disproportionately small fraction of the total T cell population in humanized 
mouse model of EBV infection using NSG and NSG-HLA-A2 transgenic 
mouse strains 155,156.  However, these studies did not report an accompanying 
cytokine assay.  Therefore, whether non-specific hyperactivation of T cells 
contributes to the death of the mice or not is still an open question.  The next 
experimental step we pursued was to study the cytokine profile in our 
humanized mice in the context of EBV infection, to understand the human 
cytokine response against the infection and to test the hypothesis that massive 
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3.2.9 Human cytokine response in infected humanized mice 
Previous reports from in vivo models of EBV infection and 
lymphoproliferative disease provide valuable insights into the effects of 
cytokines on the initiation and growth of EBV-positive tumor cells in 
immunodeficient mouse systems.  Johannessen, et al. 190 showed an increase in 
IL2, IL4, IL6, IL10, IFN-γ in B cell lymphoma induced in SCID mice.  This 
pattern was similar to the cytokine profile of activated T cells.  Since depletion 
of T cells in their experiments prevented tumor formation, activated T cells 
and the cytokine microenvironment they created may be important for 
initiation of lymphoproliferative disease, after which the established tumor can 
grow by the autocrine or paracrine cytokine support independent of T cell 
help.  This is the basis of the current notion that T cells are essential to support 
the growth of EBV-associated lymphoproliferative disease although tumor 
cells themselves can secrete autocrine growth factors like IL6 28,29. 
Human cytokine profiling in a chimeric humanized mouse setting was 
first reported in 2006 by Melkus, et al. 151, in which humanized BLT mice 
were challenged with a superantigen, toxic shock syndrome toxin-1 (TSST-1).  
The same group challenged the mice with EBV but did not report the cytokine 
profile after infection.  Shultz, et al. 156 reported intracellular cytokine staining 
of IFN-γ, IL4 and IL17 in their humanized HLA-A2 transgenic NSG mouse 
model of EBV infection but failed to show a significant difference compared 
to uninfected mice except for IFN-γ.  Johannessen, et al. 191 highlighted the 
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importance of IL2, IL7 and IL15 conditioning of CTLs in delaying the tumor 
growth and the important role of Th1 cytokine IL2 in preventing the tumor 
growth in SCID mouse model of lymphoproliferative disease.  
In this study, we employed a 17-plex human cytokine assay system on 
terminal plasma samples of 13 humanized infected and 3 uninfected mice and 
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Figure 16. Analysis of the human cytokine response against EBV 
infection assessed by multiplex human cytokine assay on humanized mice 
plasma 10 - 12 weeks after infection.  Compared to humanized uninfected 
controls (n=3), humanized infected mice (n=13) had significantly higher levels 
of Th1 cytokine TNF-α; Th2 cytokines IL4, IL6, and IL10; and chemokines 
MCP1, MIP1β and IL8; and IL17.  Statistical analysis was performed by 
student t-test with unequal variances. * p value < 0.05. ** p value < 0.01. *** 
p value < 0.001. 
 
Many of the cytokines we identified as upregulated in the humanized mice 
have a possible implication on the pathogenesis of EBV infection and 
associated pathological changes.  Since the assay was on human cytokines, 
these findings can be theoretically extrapolated to the pathogenic processes 
occurring in EBV-infected humans.  The human specificity of the cytokines 
was ascertained by using plasma samples of humanized uninfected mice of the 
same age as controls.  
The most striking observation was a marked increase in IL4, IL6 and 
IL10 in infected mice Figure 16B, showing polarization towards Th2 response 
– the same cytokine microenvironment observed in tissues from patients with 
post-transplant lymphoproliferative disease 35.  The polarized Th2 response 
and the significant increase in IL6 (an autocrine growth factor for EBV-
transformed B lymphoblastoid cells) suggests that the nature of the cells in the 
terminal stage of the disease might be very similar to that found in PTLD.   
The levels of Th1 cytokines in infected mice, however, were not 
significantly different from humanized uninfected mice controls except for 
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TNF-α Figure 16A.  According to Setsuda, et al. 25, TNF-α is not expressed in 
PTLD tissues.  However, an increase in TNF-α level was not unexpected 
because it is also known as cachexin, which is usually found in high levels in 
terminally debilitated patients, in this case, represented by infected mice at 
their terminal stage of EBV infection and associated lymphoproliferation.   
Pro-inflammatory chemokines such as monocyte chemotactic protein-1   
(MCP-1), macrophage inflammatory protein-1β (MIP-1β) and IL8 were also 
significantly raised in infected mice compared to controls Figure 16C.  This 
suggests that an acute phase response-like reaction has occurred at the 
terminal stages of EBV-related pathology in infected mice.  These chemokines 
are closely linked to granulocyte and monocyte recruitment and modulation of 
acute inflammatory response rather than the cytokine response induced by the 
chronic protracted course of disease expected of EBV-related pathology in 
immunodeficient infected mice.  Our analysis of immune cells did not contain 
non-lymphoid lineage human immune cells.  Therefore, we could not make a 
conclusive statement as to whether these non-lymphoid immune cells were 
also involved in the immune response against EBV infection and/or associated 
lymphoproliferative disease. 
 Interestingly, we also noticed a significant increase in IL17 in infected 
mice Figure 16D.  IL17 is a proinflammatory cytokine secreted by Th17 cells.  
Th17 cells were reported to elicit a stronger activation of tumor-specific CTLs 
than Th1 192 and they were also shown to eradicate established tumors in a 
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murine melanoma tumor model 193.  IL17-secreting cells also play an 
important role in the pathogenesis of autoimmune diseases.  Moreover, EBV-
induced protein 3 (EBI3) was reported to inhibit secretion of IL17, IL22 and 
thereby hampering both the innate and adaptive immunity shown in the EBI3 
deficient mice 194.  An increase in IL17 implied that Th17 cells could develop 
in our humanized NSG mice which can then be used to study this particular 
cell subset with strong proinflammatory and anti-tumorigenic properties. 
 In summary, we are the first group to investigate the comprehensive 
human cytokine and chemokine response towards EBV infection and 
associated lymphoproliferation in a humanized mouse system.  Our cytokine 
assay showed the Th2 polarized pattern found in human PTLD tissue samples 
and the increase in chemokines and acute-phase cytokines suggested possible 
involvement of non-lymphoid components of the human immune system.  
However, since the functional development of non-lymphoid immune cells in 
humanized NSG mice was not as robust and reliable as lymphoid counterparts, 
we could not provide conclusive information about the involvement of these 
cells.  The next step would be to investigate the nature of infected B cells and 
how closely they resembled to EBV-transformed B cells in the 
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3.2.10 Distribution of human B cell subsets in the spleen 
 
Figure 17. Flow cytometric analysis of splenic B cell lineages.  (A)  The 
flow cytometry plots show expression of the pre-B cell marker CD10, 
immature B cell marker IgM, B1-like B cell marker CD5, B cell activation 
marker CD40 – all gated on human CD45.  (B)  The corresponding 
quantitative data are shown on the right panel.  Black bars in the quantitative 
bar chart represent infected mice and grey bars, uninfected mice.  The 
percentages of different B cell subsets were not significantly different between 
infected and uninfected mice.  Data shown were from a representative batch of 
mice.  Student t-test was performed and the statistical significance (p value < 
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We investigated whether the natural distribution of B cell subsets was affected 
by EBV infection.  The majority of the human B cells were surface IgM-
positive immature B cells.  Our findings showed similar levels of different B 
cell developmental stages ranging from pre-B cells or germinal center B cells 
(CD19+CD10+), immature/transitional B1-like B cells (CD19+CD5+), 
immature naive B cells (CD19+IgM+) and activated B cells (CD19+CD40+) in 
both infected and uninfected mice, suggesting that EBV did not affect B cell 
development nor did it drive preferential proliferation of a particular subset of 
B cell.  This is consistent with the current concept that EBV-infected B cells 
are able to progress through physiological developmental stages and are not 
selected for any particular developmental stage 43,195.  This also suggested that 
human B cells in infected mice were not malignant because if the cells were 
malignant, there would be a preferential proliferation of a subset of B cells at 
the maturation stage from which the malignant clone arose.  We then 
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3.2.11 Clonality of splenic B cells 
In clinical diagnosis settings, B cell clonality is assessed by rapid flow 
cytometry assay using surface staining of immunoglobulin light chain gated on 
B cells.  The ratio of kappa to lambda light chains from 0.5 (lambda light 
chain restriction) to 3 (kappa light chain restriction) is consistent with mono- 
or oligoclonal expansion of the analyzed B cells 196.  
Determination of the clonality of human B cells by flow cytometric 
analysis of surface immunoglobulin light chain expression, although simple, 
rapid and widely used, is not without pitfalls.  Although light chain restriction 
is used as a surrogate marker of B cell clonality, some non-clonal expansion 
can also be light chain restricted.  For example, the non-clonal reactive 
proliferation in tonsillar specimens in childhood is often associated with 
lambda light chain restriction197; and the non-clonal B cell expansion is 
observed in multicentric Castleman’s disease – angiofollicular lymph node 
hyperplasia 198.  Conversely, some light chain restricted monoclonal 
populations are not neoplastic 199, e.g., florid follicular hyperplasia in HIV 
patients 200.  The test is not sensitive and the analysis will be polyclonal if the 
neoplastic clonal population constitutes only a small percentage of analyzed 
cells in a highly reactive neoplastic disease like Hodgkin’s lymphoma, in 
which reactive polyclonal lymphocytes are the majority.  Negative staining 
will be observed in certain stages of B cells in the developmental pathway in 
which light chains are not expressed, e.g., lymphoblasts, plasma cells, thymic 
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B cells and neoplasms arising from them.  Moreover, ongoing somatic 
hypermutation in follicular lymphoma can lead to alteration or deletion of 
recognized light chain epitopes 201.  Therefore, light chain restriction is not 
synonymous with monoclonality nor is it diagnostic of neoplasia by itself but 
it provides a valuable supportive evidence as to the clonal nature of the B cells 
and should be interpreted along with other immunophenotypic tests and 
clinical parameters. 
 
Figure 18. Clonality assay by surface expression of immunoglobulin 
light chain measured by flow cytometry.  The cell populations in the flow 
cytometry plot were gated on CD19+ human B cells.  In the quantitative chart 
below, infected mice (n=6) are shown in black squares and uninfected mice 
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According to our B cell subset phenotype data discussed in the previous 
section Figure 17, most B cells in the humanized mice were surface IgM-
positive immature B cells and so they should express immunoglobulin light 
chain on the cell surface.  As shown in Figure 18, immunoglobulin light chain 
class restriction flow cytometry assay on our infected mice consistently 
showed a polyclonal expansion of B cells except only one mouse showing a 
monoclonal kappa chain restricted phenotype.  All other infected mice had 
polyclonal B cell proliferation.  Therefore, we do not have enough evidence to 
claim that EBV-infected B cells in our mouse model were oligo- or 
monoclonal and the lesions we observed in the infected mice were malignant 
tumors despite their widespread and fatal nature.  However, as mentioned 
above, other immunophenotype and clinical parameters have to be considered 
in an integrative manner to conclusively determine the nature of the B cells in 
infected mice. 
 Pathological findings (both autopsy and histological) of EBV-infected 
mice suggested against virus-induced benign lymphoid proliferation due to the 
widespread and fatal nature of the disease, affecting various organ systems.  
However, detailed analysis of splenic B cell subsets and clonality did not 
provide conclusive evidence to claim that EBV-infected human B cells were 
malignant.  We have also excluded the contribution of human T cells in 
pathogenesis of the disease phenotype observed in the infected mice as there 
were not enough evidence to claim non-specific T cell activation and 
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hypercytokinemia.  Contribution of human T cells, if any, would be no more 
than their inability to mount mature and functional immune response against 
EBV infection and virus-induced lymphoproliferation.  Therefore, we 
proceeded to investigate the role of human B cells in disease pathogenesis.  
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3.3 DEMONSTRATION OF A PIVOTAL ROLE OF HUMAN B 
CELLS IN THE PATHOGENESIS OF DISEASE IN EBV-INFECTED 
MICE 
Human B cells in infected mice were polyclonal and the distribution of B cell 
subsets was not affected by EBV.  Although there was massive proliferation of 
T cells suggestive of non-specific hyperactivation at the terminal stage of the 
disease, detailed analyses on T cell immune response and the human cytokine 
profile in infected mice showed that the T cell hyperactivation was not likely 
to contribute to the death of the infected mice.  Therefore, we probed further 
into the role of human B cells in the pathogenesis of the disease phenotype 
observed in infected mice by specifically depleting human B cells using 
Rituximab – a specific anti-CD20 monoclonal antibody used in the clinical 
management of B cell lymphomas.  If the B cells were truly important in 
disease pathogenesis, specific B cell depletion should lead to regression of the 
lesions or provide a survival benefit for the treated mice.  This would confirm 
the pivotal role of human B cells in the development of lesions in the infected 
mice. 
Rituximab is a potent monoclonal antibody which specifically depletes 
CD20+ human B cells.  It is a breakthrough medication in the treatment of 
non-Hodgkin’s lymphomas of B cell origin and increased the survival of the 
patients who are treated with routine chemotherapy regimens with toxic side-
effects.  The mechanisms of action of the drug are induction of apoptosis202,203, 
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antibody-dependent cell-mediated cytotoxicity, complement-mediated 
lysis204,205 and chemosensitization of other drugs used in cancer 
chemotherapy202,206.     
 
3.3.1 Experimental scheme of Rituximab treatment of EBV-infected mice 
We set up a series of rituximab treatment experiments on humanized infected 
mice with relevant control groups.  We included humanized infected untreated 
controls to compare the effectiveness of treatment and humanized uninfected 
treated controls to rule out the possible side-effects of the treatment, causing 
shifts in cell populations and affecting survival.  Experimental parameters 
compared between infected treated and infected untreated mice were plasma 
viremia by qPCR, changes in peripheral blood immune cell populations by 
flow cytometry, and most importantly, the survival proportion by Kaplan-













Figure 19. Experimental scheme of rituximab treatment and depletion 
of B cells after treatment.  (A) Intravenous Rituximab treatment 1 µg/g body 
weight was administered for six weekly doses starting from the sixth week 
post-infection until eleventh week post-infection.  (B) Flow cytometry plot 
showing the depletion of CD19+ human B cells assessed 48 hours after 
Rituximab treatment.   
 
As discussed in characterization of the primary mice section (Figure 8), an 
EBV viremia peak was observed at the fourth week post-infection.  Some of 
the infected mice started to lose weight at the sixth week post-infection and 
most died by the twelfth week post-infection.  Thus, we started Rituximab 
treatment of the mice with six weekly doses of 1 µg/g body weight from the 
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sixth week until eleventh week post-infection (Figure 19A).  Rituximab 
efficiently depleted human B cells to less than 1% within 48 hours after 
treatment as assessed by flow cytometry of peripheral blood by using pan-B 
cell marker CD19 as shown above in Figure 19B.  
Since intrinsic defects in the human immune system develop in NSG 
mice include deficient development of NK cells, required for antibody-
dependent cell-mediated cytotoxicity 143 and absence of complement system 
for complement-mediated lysis 207, the two usual mechanisms attributed to 
rituximab-mediated B cell depletion are not functional.  Thus, the ability of 
rituximab to efficiently deplete human B cells in humanized NSG mice 
possibly highlights apoptotic induction as an important mechanism of action 
of this drug.   
The experimental mice were monitored for general well-being, weekly 
peripheral blood analysis and plasma viremia by qPCR and the results are 
summarized in Figure 20 and Figure 21.  Peripheral blood for viremia and 
flow cytometry analysis was obtained from the mice 48 hours after weekly 
rituximab treatment.  Survival of the humanized infected treated mice and 
humanized infected untreated mice was also compared in Figure 22.  The mice 
were monitored up to eighteen weeks post-infection. 
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3.3.2 Complete clearance of viremia after B cell depletion 
 
Figure 20. Weekly plasma viremia of rituximab treated and untreated 
mice.  Mice were treated with rituximab weekly from week six (noted by a 
black triangle) to week eleven post-infection.  (A)  Plasma viremia trend by 
qPCR from a representative batch of untreated mice (grey line) (n=4) and 
treated mice (black line) (n=7) was shown.  Dotted lines represent threshold of 
significant viremia set by background signals obtained from humanized 
uninfected mice.  (B)  Viremia was completely abolished in Rituximab-treated 
mice (black) while untreated mice (grey) showed a periodic reactivation 
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Plasma EBV viral DNA levels of treated and untreated mice were comparable 
before treatment, i.e., week six on the respective figures.  Viremia in infected 
untreated mice showed a cyclical pattern and a steady rise towards the 
experimental end point (see Figure 20A).  However, in infected treated mice, 
we observed a decline in plasma EBV DNA load after week six and almost 
cleared below the negative threshold line from week eight post-infection 
which was after the third dose of rituximab (see Figure 20B).  This showed the 
effectiveness of rituximab treatment in terms of reduction in human B cells 
and virus clearance from the circulation and also suggested that EBV is 
confined to the human B cell compartment in infected mice.  A lag time of two 
weeks before the viremia was completely abolished in treated mice may be 
due to the release of virus particles from the Rituximab-treated B cells after 
the first two doses of the treatment.  
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3.3.3 Immune correlates of rituximab-treated mice 
 
Figure 21. Comparison of distribution of peripheral blood immune 
cells in rituximab treated and untreated mice.  Mice were treated with 
rituximab weekly from week six to week eleven post-infection.  Human 
CD45+ cells (A) were gated on DAPI- live cells; B and T cells (B, C) were 
gated on human CD45+ cells; CD4 and CD8 cells (D, E) were gated on T 
cells; and CD95+ B cells and HLA-DR+ T cells (G, H) were gated on human 
B and T cells respectively.  Data was from a representative batch of rituximab 
treatment experiment.  Black lines represent data from treated mice (n=7) and 
grey lines, untreated mice (n=4).  Statistical significance was tested by 
student-t test for individual time points and ANOVA for overall trend and is 
represented by asterisk (*). 
 
 




    118 
 
Peripheral blood absolute cell counts of infected treated mice showed total 
depletion of human B cells (Figure 21B) after rituximab treatment (week six) 
and thus, CD95-positive B cell counts (Figure 21G).  Compared to infected 
untreated mice, total T cell populations (Figure 21C) in infected treated mice 
were not significantly different.  CD8:CD4 ratio in infected treated mice was 
significantly increased one week after the onset of treatment (week seven) but 
the overall trend was the same as that in untreated mice (Figure 21F).  
However, CD8+ CTL counts increased starting from week seven, i.e., one 
week after treatment, and maintained until the end of the treatment regime 
(week eleven) after which CTL population declined (Figure 21E).  This might 
be due to the sustained CTL response against more prolonged presence of the 
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3.3.4 Survival benefit of rituximab treated mice – Evidence that B cells are 
the major driving force in the pathogenesis of the disease  
 
 
Figure 22. Kaplan-Meier survival analysis of rituximab treated mice 
showed survival benefit with B cell depletion.  Infected treated mice (n=13) 
were represented by interrupted line with squares, infected untreated mice 
(n=11) by dotted line with circles, and uninfected treated control (n=5) by 
solid line with triangles.  Tables of results of statistical analyses were also 
shown.  The median survival of Rituximab treated mice were 91 days while 
that of untreated mice were 75 days.  The survival proportions were shown to 
be significant by using Mantel-Cox log-rank test and Gehan-Breslow-
Wilcoxon tests with the p-values of 0.0080 and 0.0283 respectively. 
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As shown in Figure 22, rituximab treatment significantly prolonged the 
survival of the humanized infected treated mice (average life span 91 days, 
range 41 – 82 days) compared to humanized infected untreated mice (average 
life span 75 days, range 47 days – experimental end point of 130 days).  The 
survival of uninfected mice was not affected by rituximab treatment, implying 
that the drug did not have any adverse effects on humanized NSG mice apart 
from depletion of human B cells.   
The observed survival benefit of rituximab treatment indicates that the 
pathological changes in infected primary mice were driven by human B cells, 
and thus, by EBV infection.  Infected treated mice still died despite treatment 
because the treatment was initiated with a therapeutic intent after the disease 
has occurred rather than a preventive intent to protect the mice from the 
disease.  Therefore, we chose the time point when the pathological changes 
were strong enough to manifest as a detectable disease which shortened the 
lifespan of the infected mice compared to uninfected treated mice controls. 
 We now have strong evidences that human B cells play a pivotal role 
in the pathogenesis of the disease in EBV-infected mice although they 
constituted a relatively minor population in the peripheral blood and the 
spleen, compared to T cells which occupied the majority of the human 
immune cell compartment.  However, this does not prove that the human B 
cells in EBV-infected mice have a malignant potential despite the widespread 
and fatal nature of the disease, favoring a diagnosis of a malignant tumor.  To 
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address this question, we employed the secondary adoptive transfer method to 
investigate the nature of human B cells in EBV-infected mice.  
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3.4 EXPERIMENTAL PROOF OF THE MALIGNANT NATURE OF 
HUMAN B CELLS IN EBV-INFECTED MICE 
EBV-associated post-transplant lymphoproliferative disease occurs in patients 
receiving T cell immunosuppressive therapy which is given to prevent the 
alloimmune response against a transplanted organ or tissue graft.  Latent EBV 
infection in immunocompetent persons is totally asymptomatic and the virus 
resides in the memory B cells of the host for life without any pathological 
consequences.  In short, EBV is benign in immunocompetent hosts and causes 
fatal lymphoproliferative disease in immunodeficient populations. 
 We have demonstrated the establishment of latent EBV infection in our 
humanized mouse model, leading to fatal systemic lymphoproliferation.  
These observations are consistent with the sequence of pathophysiological 
events occurring in immunodeficiency-related lymphoprolifeative disease.  
However, the human B cells in the infected mice were polyclonal – a fact 
which hindered us from claiming that human B cells in our mouse model were 
capable of forming malignant lesions which were almost invariably 
monoclonal or oligoclonal in nature.  Therefore, we tested the hypothesis that 
human B cells in latently infected mice were tumorigenic by secondary 
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3.4.1 Experimental scheme of secondary adoptive transfer experiments 
 
 
Figure 23. Experimental scheme of secondary splenocyte transfer 
experiments.  Infected mice were euthanized at week 12 post-infection, 
splenocytes were isolated and the single cell suspension was prepared.  
Unfractionated splenocytes were then injected intraperitoneally into adult non-
humanized NSG mice as secondary recipients without sublethal irradiation.  
Control mice were injected with unfractionated splenocytes from humanized 
uninfected primary mice.  
  
We euthanized the primary mice at the twelfth week post-infection and 
isolated splenocytes from both infected and uninfected mice.  Fresh ten 
million unfractionated splenocytes were injected intraperitoneally on the same 
day into eight to ten week old adult male NSG mice without any pre-
conditioning myeloablative treatment, such as sublethal irradiation.  An 
approximately equal number of splenocytes from the humanized uninfected 
mice were injected into the control group to show that any potential 
tumorigenic effect was specific to infected cells.  Since the mouse immune 
system in non-humanized NSG mice is severely weakened, the secondary 
recipients were severely immunodeficient like those patients receiving post-
transplant immunosuppressive therapy.  The mice were monitored for signs of 
disease for up to 20 weeks and the life spans of the experimental groups were 
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compared.  The results of the splenocyte secondary transfer experiments are 
summarized below.  
 
3.4.2 Life span of secondary mice 
 
Figure 24.  Survival of secondary mice injected with unsorted total 
splenocytes of infected and uninfected humanized mice of the same age.  
All the mice injected with cells from infected mice died within 6 – 16 weeks 
while those injected with cells from uninfected control mice survived until the 
experimental end-point of 20 weeks.  Data were obtained from two 
independent batches of secondary splenocyte transfer experiments.  The 
number of injected B cells was calculated from absolute splenocyte counts 
after isolation and the percentage of B cells obtained by flow cytometry.   
 
According to flow cytometric analysis on the proportions of human cell 
compartments, ten millions of unfractionated splenocytes contained 0.87 - 
1.73 millions of human B cells injected into secondary hosts.  We observed 
that only those mice injected with at least one million human B cells 
developed fatal lesions within six to fifteen weeks after adoptive transfer.  
Control mice injected with splenocytes from humanized uninfected mice did 
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not develop any signs of disease and survived until the experimental end-point 
of 20 weeks.  We could not allocate an equal number of control mice because 
of a poor yield of human B cells from uninfected humanized mice at 12th week 
post-infection (24th week post-humanization or 24th week of age), due to a low 
percentage of human B cells at this age - an intrinsic phenomenon of 
humanized NSG mice in which the human B cell population declined as the 
mice age. 
A detailed analysis of the lesions observed in the secondary mice is 
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3.4.3 Appearance of systemic fatal tumors in secondary mice which 
received unfractionated splenocytes 
 
 
Figure 25. Fatal systemic lesions in secondary mice and expansion of 
human cells in secondary spleens.  (A) Discrete multifocal tumors were 
observed in the liver, kidneys and peritoneal cavity of secondary mice.  
Peritoneal tumor was matted with coils of intestine.  (B) Fold expansion of the 
absolute numbers of both human B and T cells in the spleens of the secondary 








    127 
 
On autopsy of mice in our secondary transfer experiments, we observed white 
tumor masses matted with coils of intestine in the peritoneal cavity as shown 
in Figure 25A above.  On cut section, the tumor was pale, fleshy and firm in 
consistency.  There were discrete multifocal pale tumors in the kidneys and 
the liver.  Surprisingly, the spleens were devoid of visible tumor deposits as 
they were major organs affected in EBV-infected primary mice.  Control mice 
were normal and did not have any visible lesions.   
 Flow cytometry on isolated secondary splenocytes showed marked 
expansion of total human cells, human B and T lymphocytes compared to the 
number of injected cells (see Figure 25B).  The majority of the human cells in 
secondary spleens were human T cells which were similar to the proportion of 
human B and T cells observed in primary mice.  No human cells were detected 
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3.4.4 Activated human cells in the spleens of secondary mice which 
received unfractionated splenocytes 
 
Figure 26. Flow cytometry of the splenocytes of the secondary mice 
showing activation markers CD95 and HLA-DR on human B and T cells.  
Almost all human B and T lymphocytes in secondary mice were CD95-
positive and approximately 60% of T lymphocytes and more than 70% of B 
lymphocytes showed HLA-DR-positive activation phenotype.  
 
Flow cytometric immunophenotyping of the expanded human cells in the 
spleens of secondary mice which received splenocytes from infected primary 
mice showed that almost all the human B and T cells were strongly positive 
for activation markers CD95 and around 60% of T cells and more than 70% of 
B cells showed HLA-DR+ activation phenotype.  Similar to the activation 
status of the splenocytes in infected primary mice (see Figure 14), both B and 
T cells strongly expressed activation marker CD95.  The percentage and 
absolute counts of HLA-DR+ human T cells in infected primary mice, 
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however, were not different from those in uninfected mice and only a small 
percentage (< 5%) of T cells were HLA-DR positive.  In the secondary mice, 
around 60% of T lymphocytes were activated according to the HLA-DR 
expression profile as shown in the lower panel of Figure 26.  This striking 
difference in activation marker expression could be due to the response of the 
accompanying B cells co-injected during secondary adoptive transfer.  Since 
splenocyte preparation steps included several washing steps, there was no 
chance of virus contamination in the injected cell preparation so it was 
unlikely to be the virus which activated the T cells, resulting in their 
expansion. 
Therefore, we concluded that transferred human T cells were primed to 
elicit an anti-EBV immune response in the primary hosts and were reactive to 
EBV-infected cells in the secondary mice.  The significant response seen in 
the secondary mice (not in the primary mice) suggested that the nature of 
stimulus which caused T cell expansion and activation were different in the 
primary and secondary mice.  Human T lymphocyte immune response in the 
primary mice was most likely against the virus and that in the secondary mice 
was most likely against the expanded B cells which formed systemic tumors in 
the severely immunodeficient secondary host. 
The tumorigenicity assay by secondary splenocyte transfer into 
severely immunodeficient mice clearly demonstrated the existence of 
tumorigenic cell clones in the primary EBV-infected mice.  We then dissected 
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the nature of tumorigenic cells by sorting human B cells from the spleens of 
EBV-infected primary mice and performed the tumorigenicity assay in a 
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Figure 27. Experimental scheme of secondary splenocyte transfer 
experiment using sorted human B cells.  Infected mice were euthanized at 
week 12 post-infection, splenocytes were isolated and sorted for human B 
lymphocytes.  One million fractionated B cells were then injected 
intravenously into adult non-humanized NSG mice as secondary recipients 
without sublethal irradiation.  Control mice were injected with non-B cell 
fraction from infected mice or human B cell fraction from humanized 
uninfected mice.  
 
We sorted splenocytes before secondary transfer using CD19 positive 
selection immunomagnetic beads.  We injected sorted B cells (positive 
fraction) intravenously into a set of un-preconditioned adult non-humanized 
male NSG mice of eight to ten weeks of age, similar to the secondary adoptive 
transfer experiments discussed above.  Positive fraction sorted B cells from 
uninfected primary mice were injected into the control group as well.  Cells in 
the negative fraction, containing human T cells in the majority, were injected 
into another set of control NSG mice using the same experimental protocol to 
investigate if the secondary tumor formation was exclusively by B cells and 
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not by other human immune cells.  The mice were monitored and the lifespan 
was compared and summarized below in Figure 28.    
 
Figure 28.  Survival of secondary mice injected with sorted splenocytes 
from infected and uninfected humanized mice of the same age.  Isolated 
splenocytes were sorted using CD19 positive selection immunomagnetic beads 
and one million cells from positive or negative fractions were injected into 
unconditioned secondary recipient adult male NSG mice.  The life span of 
respective experimental groups is shown in parentheses. 
 
  
All of the secondary mice which received sorted B cells from infected primary 
mice developed fatal disease five to nine weeks after cell injection while all 
the mice in the two control groups survived up to the experimental endpoint of 
20 weeks.  The striking difference in the life spans of different experimental 
groups of secondary mice clearly demonstrated that the pathology was specific 
to those mice which received human B cells from EBV-infected primary mice.  
The human B cells from uninfected primary mice and non-B cells in EBV-
infected primary mice did not develop into any discernible pathology, if any.  
 
 




    133 
 
Human B cell component in EBV-infected mice were therefore capable of 
developing into a fatal disease state under severely immunocompromised 
conditions.  Tissue lesions observed in secondary mice which received sorted 
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3.4.6 Tissue lesions in secondary B cell tumor mice 
 
 
Figure 29. Kidney lesions in secondary mice which received sorted B 
lymphocytes and demonstration of human B lymphocytes in the lesions.  
(A) Tumor formation of various sizes in the kidneys of secondary mice 
injected intravenously with sorted B cells.  (B) Flow cytometry plots of a 
representative secondary mouse showed human B cells in kidney lesions.  The 
spleen and the bone marrow of the same mouse were virtually devoid of 
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Secondary tumors in the kidneys and bilateral renal enlargement with 
distortion of tissue architecture were observed in the mice which received 
sorted human B cells from EBV-infected primary mice.  Small multifocal 
lesions were also observed in the liver while the spleen and the lungs were 
devoid of visible lesions.  Flow cytometry on the isolated cells from the 
kidney tumor showed human B cells exclusively in the kidneys while the 
spleen and bone marrow were devoid of human B cell.   
 These striking observations prove that human B lymphocyte 
population alone was both necessary and sufficient to form the tumors and the 
human B cells from EBV-infected individuals had a malignant potential under 
severely immunocompromised conditions.  In other words, this represents a 
direct causal link between EBV and the development of an immunodeficiency-
related lymphoid malignancy.   
 We then characterized the secondary lesions by histopathological 
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3.4.7 Histopathological examination of secondary tumors 
Histopathological examination of the intraperitoneal tumors and the spleen of 
secondary mice showed that the lesions induced by injected splenocytes were 
indeed originated from EBV-infected human B cells.   
 
 
Figure 30. Histopathological examination of lesions in secondary mice.  
(A) Hematoxylin-Eosin staining of the secondary intraperitoneal tumor and 
immunohistochemical staining of the secondary tumor and the spleen with 
human B cell marker CD20 and human T cell marker CD3.  The secondary 
tumor was formed by human B cells while the secondary spleen was infiltrated 
with T cells in the majority.  (B) Strong LMP1 staining in secondary 
intraperitoneal tumor and mass lesions in the secondary kidney show the 
presence of EBV in the lesions.  Figure insets showed a higher magnification 
picture of the stained cells. 
 
 




    137 
 
Hematoxylin-Eosin staining of the intraperitoneal tumor showed a large 
amount of mononuclear cells scattered in amorphous, acellular, eosinophilic 
matrix.  The cells did not form any well-defined follicular structure.  Cross 
sections of coils of intestine were noted in the periphery of the tumor, showing 
that the tumor was tightly matted with surrounding structures like intestinal 
loops (Figure 30A, left panel).   
Immunohistochemistry stains showed that the intraperitoneal tumors 
were almost entirely composed of human B cells (Figure 30A, middle panel) 
with a few T cells scattered in the tumor matrix (Figure 30A, right panel).  The 
staining pattern of the secondary spleen confirmed the flow cytometry results 
and showed expanded human B cells but the majority of the infiltrating cells 
were T cells.  There was a marked differential distribution of the B and T cells 
in the secondary spleen and secondary tumors which were almost entirely 
composed of human B cells with very few T cells scattered in the tumor 
matrix.  This finding suggested that reactive T cells reside in the spleens while 
the tumor-initiating cells were B cells with very little contribution from 
accompanying T cells.  A latent EBV protein LMP1 was also demonstrated in 
the secondary tumor and in the secondary lesions in the kidney (Figure 30B).   
The widespread occurrence of the tumors, the fatal nature of the 
disease and the fact that those lesions were almost entirely composed of EBV-
infected human B cells implied that the malignant clones of EBV-infected B 
cells in the primary mice were selected in vivo in the secondary 
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immunodeficient host and grew out as autonomous tumors in spite of some 
evidences of T lymphocyte immune response in the spleen. 
 The fatal and systemic nature of the lesions in the secondary mice 
proved our hypothesis that EBV-infected B cells in the primary mice had a 
malignant potential.  We further proceeded to detailed characterization of the 
secondary tumors as regards to the nature of the tumorigenic B cells and the 
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3.4.8 Demonstration of latency III pattern of EBV gene expression in 
secondary tumors 
 
Figure 31. Immunohistochemistry staining of secondary tumors to 
determine EBV latency.  Secondary tumors stained positively for LMP1 and 
EBNA2.  Co-expression of EBNA2 and LMP1 represents latency III program 
of EBV gene expression.  Figure insets show a higher magnification picture of 
the stained cells. 
 
Immunodeficiency-associated lymphoproliferative lesions are typically 
composed of human B cells expressing a latency III pattern of EBV gene 
expression.  As mentioned in Table 1, EBV latent gene expression programs 
can be differentiated by using expression of EBNA2 and LMP1.  Expression 
of both EBNA2 and LMP1 is consistent with latency III program; LMP1 
without EBNA2 is consistent with latency II and neither EBNA2 nor LMP1, 
latency I.  We stained secondary tumor tissues with specific antibodies for 
EBNA2 and LMP1 and the lesions were found to be positive for both latent 
proteins.  Therefore, tumorigenic B cells in the lesions expressed latency III 
program of latent gene expression similar to the immunodeficiency-associated 
EBV-linked post-transplant lymphoproliferative lesions in human beings.   
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3.4.9 Demonstration of cellular proteins in secondary tumors 
 
Figure 32. Immunofluorescent staining of secondary tumor tissues 
with human B cell marker CD20, anti-apoptotic protein Bcl-2, pre-
germinal center B cell marker CD77 and death receptor Fas or CD95.  
The left panel showed CD20 stained with AF488 (green), the middle panel 
showed respective cellular proteins stained with AF546 (red), and the right 
panel showed the merged images (yellow staining in the merged images 
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Further detailed histopathological analysis of the secondary tumors showed a 
diffuse CD20 staining pattern for human B cells co-localized with strong 
staining for the anti-apoptotic protein Bcl-2, pre-germinal center B cell marker 
CD77 and death receptor (Fas) CD95 (Figure 32).   
Strong expression of Bcl-2 suggests that the B cells in the lesions were 
actively dividing cells.  Bcl-2 is a cellular proto-oncogene with anti-apoptotic 
properties and is upregulated by a putative EBV oncoprotein, LMP1, through 
activation of NF-κB pathway as discussed in Section 1.3.3. Latency II or 
growth program. 
The fact that the tissue sections were strongly positive for CD95 
suggested the activation status of the virus-infected human B cells which was 
consistent with flow cytometric characterization of splenocytes in secondary 
mice as shown in Figure 26.  Secondary tumor cells also appeared to be 
resistant to CD95-induced apoptosis because they proliferated into 
macroscopic tumors even though they were tagged with the death receptor 
CD95.   
CD77 is a marker for the centroblast stage of germinal center reaction 
and is downregulated once B cells mature into centrocytes 184,208.  Therefore, 
secondary tumors appeared to originate from germinal center centroblast-like 
cells, similar to post-transplant lymphoproliferative disease and Burkitt’s 
lymphoma.     
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In conclusion, we now have strong direct evidences that EBV-infected 
B cells per se are tumorigenic without requiring any help from T cells or other 
humoral factors except those autocrine factors secreted by B cells themselves.  
Our study has now unambiguously settled the decade long controversy as to 
the tumorigenic nature of EBV and we have demonstrated strong experimental 
evidences to claim that EBV is not just an innocent by-stander but the virus 
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CHAPTER 4 :  DISCUSSION 
The humanized mouse model of EBV infection successfully established by our 
group demonstrates salient features of latent EBV infection and an EBV-
induced human immune responses.  We have also shown that human B cells in 
infected mice play a pivotal role in disease pathogenesis by depletion of B 
cells using Rituximab – a therapeutic monoclonal antibody specifically 
targeting CD20-expressing human B cells.  Secondary adoptive transfer 
experiments proved the malignant potential of EBV and the infected B cells in 
the lesions of the primary mice.  This is the first study which provides strong 
direct evidence on the malignant potential of EBV-infected B lymphocytes 
and proves that EBV is a causative agent rather than an innocent by-stander in 
associated diseases. 
 We are also the first group to report a comprehensive cytokine profile 
in a humanized NSG mouse model of EBV infection.  We observed that the 
cytokine microenvironment in our mice was very similar to that in the post-
transplant lymphoproliferative disease in human.  We have also discovered 
tumor-specific expression of the centroblast marker CD77 and proposed its 
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4.1 DISEASE PHENOTYPE OF THE EBV INFECTION IN OUR 
HUMANIZED MOUSE MODEL 
Our humanized infected mice modeled the natural course of EBV infection in 
the primary mice and the fatal and florid systemic lymphoproliferative disease 
under severely immunodeficient conditions in the secondary mice.   
We have demonstrated the virologic latency and plasma viremia with 
periodic reactivation in the primary mice Figure 8B.  The rising virus titer in 
infected mice at later time points is similar to the clinical picture of transplant 
recipients before development of post-transplant lymphoproliferative disease 
(PTLD) which is almost universally preceded by the rising EBV titer in the 
PBMC or detectable viral DNA in the peripheral circulation 209-212.  A fall in 
viral load is usually associated with a treatment response after adoptive 
immunotherapy212 in a clinical setting.  In addition, the pathological changes 
observed in the infected mice and the trend of human immune cell components 
mimicked the sequence of events in the natural course of the EBV infection, 
progressing to immunodeficiency-related lymphoproliferative disorder.  
Therefore, our mouse model is a closer parallel to the human disease 
compared to previously published EBV infection models whereby functional 
EBV-specific T cell immunity has a role to play in B-cell based 
lymphoproliferation.  The pathophysiological process of our model appear 
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4.2 HUMAN IMMUNE RESPONSES IN OUR MOUSE MODEL 
We have shown that human T cells, more specifically CD8+ CTLs, were 
increased in the peripheral blood (see Figure 9) and the spleens (see Figure 13) 
of EBV-infected primary mice – immunological features suggestive of a CTL 
response but the detailed analysis of memory T cell subsets failed to show the 
development of significant immunological memory (see Figure 15).  We 
observed a significantly lower percentage of human B cells in infected mice 
spleens and a significantly higher population of CD95+ human B cells in the 
peripheral blood as well as in the spleen.  These observations plus an increased 
CD8:CD4 ratio strongly suggested that EBV-infected B cells were eliminated 
by CD8+ CTLs via Fas-mediated apoptosis (see Figure 10B and Figure 14A). 
Yajima and colleagues also studied the important role of T cells, 
specifically CD8+ CTLs, in the pathogenesis of EBV-induced disease in 
humanized NOG mice 153,154.  According to reports by the same group, 
survival of the infected mice was markedly reduced upon depletion of CD3 
and CD8.  The researchers claimed that diminished survival was due to a lack 
of a CTL immune response, which allowed uncontrolled proliferation of B 
cells resulting in an accelerated course of the disease.  The same group also 
reported MHC class I-restricted CTL response by IFN-γ ELISPOT assay and 
demonstrated HLA-restricted immune responses in infected humanized NOG 
mice.  Similarly, MHC class I-restricted IFN-γ ELISPOT after ex vivo 
stimulation of splenic T cells with autologous B lymphoblastoid cells was first 
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reported by Melkus, et al. 151 in  the humanized bone marrow, liver, thymus 
transplant (BLT) NOD/SCID mouse model of EBV infection.  
Despite close similarities with the human disease phenotype and 
immunological features suggestive of T cell immunity, the development of the 
immunological memory observed in this mouse model is suboptimal.  
However, our results are comparable to previously reported results for the 
EBV immune response in similar humanized native immunodeficient mouse 
models.  In contrast, HLA-A2 transgenic humanized mice and humanized 
BLT mice showed EBV-specific T cell responses in vivo.  The functional 
immaturity of the immune response observed in our NSG mouse model is 
hypothesized to be the result of a lack of exposure of developing human T 
lymphocytes to human antigens in the mouse thymus and a lack of optimal 
human cytokine milieu and interacting factors such as functional complement 
system, NK cells and dendritic cells. 
 Regarding the development of immunological memory, Shultz, et al. 
156 reported that the proportions of different memory T cell subsets were 
comparable between uninfected humanized NSG mice and HLA-A2 
transgenic NSG mice.  When the HLA-A2-NSG mice were infected with 
EBV, there was a significant increase in the effector memory cell population 
compared to uninfected controls but the comparison with infected NSG mice 
was not reported.  In contrast to infected NSG mice, infected HLA-A2-NSG 
mice showed EBV-specific CD45RO+ splenic memory T cells by using 
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BMLF1 and LMP1 tetramers.  These experimental evidences suggest that the 
thymic education of T lymphocytes with human HLA-A2 enhances the 
development of immunological memory and an HLA-restricted immune 
response can occur in NSG mice in which mature T cells are selected in the 
mouse thymus.   
We raised a hypothesis that ‘non-specific’ T cell activation with 
cytokine storm might contribute to the death of the infected mice based on the 
fact that there was massive proliferation of human T cells in the spleen of 
infected mice compared to the B cell population at the terminal stage of the 
disease.  A more specific way of proving or disproving that hypothesis 
requires a comprehensive array of tetramers to detect the frequency of EBV-
specific T cells and to show the disproportionately low virus-specific T cells in 
the midst of massive T cell proliferation with release of high levels of 
cytokines and chemokines.  Strowig and colleagues demonstrated that T cells 
were ‘primed’ after in vivo EBV infection, resulting in the HLA-restricted 
EBV-specific T cell immunity by IFN-γ ELISPOT assay 155.  However, the 
group could not show any tetramer-positive T cell populations in infected 
NSG mice.  However, they managed to show that 2% of the CTLs were 
positively stained for tetramer specific to HLA-A2-restricted lytic antigen 
BRLF1 epitope when NSG-HLA-A2 transgenic mice were used for infection.  
They failed to show positive LMP2 tetramer staining even though the cells 
gave a strong in vitro IFN-γ response upon stimulation with EBV-peptide 
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pools.  A detectable immunodominance pattern of latent EBV antigens in 
humanized mice was different from that found in human studies, e.g., the 
majority of the EBV-specific T cells target EBNA3 in humans but LMP2-
specific T cells were found to be dominant in humanized mice.  The findings 
of this study implied that the frequency of the EBV-specific T cell population 
was disproportionately very low compared to massive expansion of total T 
cells and CTLs even in the HLA-A2 transgenic system.  However, without an 
accompanying cytokine data, whether non-specific hyperactivation of T cells 
contributes to the death of the mice or not is still an open question.   
These previous reports did not mention the cytokine response except 
IFN-γ secretion.  Shultz and colleagues reported a similar observation and 
attributed the IFN-γ response to the thymic education in the milieu of HLA-A2 
expressing thymocytes 156.  But the IFN-γ response in humanized NOG mice 
reported by Melkus, et al. 151 and Yajima, et al. 153 cannot be disregarded 
because the development of the human immune system and the immune 
response in NOG mice harboring the truncated version of the IL2Rγ chain 
may be different from that of NSG mice which lack the IL2Rγ chain.   
We are the first group who report a comprehensive cytokine assay in 
EBV-infected humanized NSG mice.  As shown in Figure 16, the 
comprehensive human cytokine profile in our study failed to show significant 
hypercytokinemia.  Therefore, we have ruled out hyperstimulation of T cells 
with hypercytokinemia as a cause of death of the EBV-infected mice.  We 
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hypothesized that the human immune response may have been potent enough 
to suppress the virus replication but failure of development of immunological 
memory may explain the inadequacy of the immunological control resulting in 
the death of the infected mice in later stages of the disease in our mouse 
model.   
Th1 cytokines are implicated in the pathogenesis of acute lytic EBV 
infection (infectious mononucleosis) but they are not raised in the sera of the 
patients with lymphoproliferative diseases.  The Th1 cytokine profile in our 
findings in the humanized mouse model is consistent with this fact because 
only TNF-α was significantly raised among Th1 cytokines, reflecting the 
chronic state of the infection in infected mice and indirectly ruling out the 
contribution of the acute lytic infection in the pathogenesis of the 
lymphoproliferative disease observed in the infected mice.   
Another piece of evidence that makes our model more human-like is 
the Th2-skewed cytokine profile in terminal plasma samples which is similar 
to that found in PTLD tumor tissues, reflecting that the human immune system 
developed in the mice can orchestrate the cytokine response against the 
disease in a pattern similar to human patients.  However, the significant 
increase in the CCR5+ Th1 cell population in the spleens of the infected mice 
possibly reflects the balanced equilibrium between the cellular Th1 response 
and the humoral response of Th2.  Therefore, in our mouse model, the cellular 
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and humoral arms of the adaptive immune system may be acting 
complementary to each other in an attempt to eliminate the disease. 
The significant increase in the acute phase chemokines such as IL8, 
MCP-1, MIP-1β was most probably induced by massive tissue damage evident 
by the wide areas of necrosis in the spleen and the liver but the involvement of 
myeloid cells in response to the above-mentioned chemokines could not be 
inferred since the myeloid cell reconstitution was very poor and we did not 
investigate this particular compartment in our analysis.  
A significantly higher IL17 levels in infected mice suggested the 
possible development of this cytokine in the humanized mouse system.  This 
finding paved the way for future studies on the role of this cytokine and Th17 
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4.3 PROOF OF TUMORIGENICITY OF HUMAN B CELLS IN 
EBV-INFECTED MICE 
This is the first study where the gold standard methodology for determining 
tumorigenesis has been employed in EBV infection, i.e., the secondary 
transfer of the tumor-like lesions from the primary mice to secondary 
immunodeficient recipients.  Early experimental reports on the proof of the 
tumorigenic potential of EBV-infected cells used NOD/SCID mice injected 
with peripheral blood mononuclear cells from EBV seropositive donors or 
with cyclosporine A-selected lymphoblastoid cells after in vitro culture to 
allow outgrowth of EBV-infected B cells 146,147.  The disease onset and the 
lifespan were variable and ranged from 10 to 20 weeks which was similar to 
the lifespan of our secondary mice (9 – 16 weeks).   
We demonstrated that the splenocytes in EBV-infected primary mice 
did not express CD77 (see Figure 12) but the tumor lesions in secondary mice 
strongly expressed CD77.  There are two explanations to explain the 
discrepancy.  One explanation is that EBV-infected human B cells acquired 
additional cellular genetic changes that drive maturation of primary B cells 
into centroblasts.  An alternative explanation is that CD77+ B cells constituted 
a minority of the human B cell population in the primary mice and they were 
eventually selected in vivo in the secondary mice.  The differential expression 
of CD77 in infected tissues and tumor lesions suggested that CD77 may 
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provide an important signal to favor the survival of the B cells in vivo and may 
be useful as potential therapeutic target in EBV-associated lymphoid tumors.       
On the other hand, CD77 is a marker specific for centroblast stage of 
germinal center B cell maturation, implying that human B cells in secondary 
tumors were driven into germinal center maturation process but arrested at the 
centroblast stage.  The latent gene expression profile in secondary tumor 
tissues showed a latency III pattern (growth program), i.e., the tumor cells 
stained positive for EBNA2 and LMP1 (Figure 29).  EBNA2 is a potent 
transcriptional transactivator of other EBV genes and LMP1, a CD40 ortholog, 
provides anti-apoptotic signals for long-term survival of virus-activated B 
cells.  Together with LMP1, LMP2 expressed in latency III program (not 
investigated here) is a BCR analog and provides the necessary signals for B 
cell survival and differentiation into memory cells without the need for the 
signals provided by T cells and antigen exposure.  If latency III genes were 
expressed in secondary tumor cells which proliferated in large numbers 
systemically in the host, the fact that B cell development was arrested at the 
centroblast stage was a mystery.  Some other non-viral factors might be 
involved in maturation arrest without affecting virus-induced cell 
proliferation.   
Latency III gene expression program in secondary tumors, however, 
provided a mechanistic insight into the continued survival of human B cells, 
leading to tumor formation despite a strong expression of the death receptor, 
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CD95, in these cells.  Latency III gene products appeared to have provided the 
tumor cells with the survival signals stronger than the apoptotic signals 
triggered by CD95.   
A more detailed characterization of the nature of secondary tumor cells 
will be required in terms of cellular gene expression, different B cell subset 
markers and immunoglobulin gene rearrangement studies to define the 
maturation stage of these malignant cells with the ultimate goal of proposing 
novel therapeutic strategies targeted to tumor cells.   
In conclusion, our humanized mouse model of EBV infection is very 
valuable to study different virological, immunological and therapeutic aspects 
of human-specific infections like EBV in a holistic manner at the system level.  
Furthermore, based on the observations on CD95 and CD77 expression, our 
mouse model is a valuable tool for assessment of novel therapeutic strategies 
such as induction of apoptosis by manipulating latency III proteins or by 
augmenting CD95-mediated cytotoxicity and application of a monoclonal 









    155 
 
4.4 FUTURE DIRECTIONS 
Establishment of the humanized mouse model of EBV infection and 
associated lymphoproliferative disease and proof of the malignant potential of 
EBV-infected B cells is the mere first step of our relentless effort to 
understand the intricate nature of the host-EBV interaction.  As a continuation 
of the study, we will focus on molecular factors implicated in the pathogenesis 
of the lesions found in the mice and we will compare our findings to the 
human disease.   
Another approach to better understand host-EBV interaction is to boost 
the underdeveloped human immune cell populations (e.g. myeloid lineage 
cells, dendritic cells, NK cells, etc.) and thus raise the functionality of the 
human immune system as close to that in human counterparts.  Preliminary 
experiments are ongoing using hydrodynamic gene delivery method to 
enhance the functional maturation of human B and T cell populations and the 
impact on the infection process and disease phenotype.   
The third project conceived from this study is to develop a robust 
PTLD tumor model using the human hemopoietic progenitor cells and in vitro 
EBV-immortalized autologous human B cells from the same donor.  The aim 
of this study is to develop the syngeneic PTLD model, to investigate the 
immune responses in the syngeneic setting, and ultimately, to test and predict 
response to therapeutic agents and novel therapeutic strategies, leading to 
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personalized medicine and tailor-made treatment options for this fatal disease 
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